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ABBREVIATIONS
STEROID NOMENCLATURE
The following list defines the trivial names used in this
thesis.
Trivial Name
Aetiocholanolone (Aetio)
Androstanedione
Androsterone (Andro)
Androstenedione (A)
Cortisol
Dehydroepiandrosterone (DHEA)
Dehydroepiandrosterone
sulphate (DHEAS)
Diethylstilbesterol (DES)
5«-Dihydrotestosterone (5 -DHT)
Oestradiol (E2)
Oestrone (E1)
Progesterone
R1881 (methyltrienolone)
R~020 (Promegestone)
R-2956
Testosterone (T)
Systematic Name
3~-Hydroxy-5~-androstan-17-one
~-Androstane-3,17-dione
3~-Hydroxy-5~-androstan-17-one
4-Androstene-3,17-dione
11~ -170(,21-Trihydroxy-4-
pregnene,-3,20-dione
3~-Hydroxy-5-androsten-17-one
3~-Hydroxy-5-androsten-17-one-
3-sulphate
3,4-bis(4-Hydroxyphenyl)-hex-
3-ene
17p-Hydroxy-5~-androstan-3-one
1,3,5 (10)-oestratriene-3, 17~
-diol
3-Hydroxy-1,3,5(10)-
oestratriene-17-one
4-Pregnene-3,20-dione
17~ -Hydroxy-1 70(-methyl- 4,9,11
oestratrien-3-ene
170( -,18,21-trimethyl-4,9(10)-
pregnadiene-3,20-dione
17~-Hydroxy-2(J(,2",1 7cc-trimethyl
4,9,11, oestratrien-3-one
17~ -Hydroxy-4-androsten-3-one
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AR
BOMT
BSA
cpm
cv
eBG
Dec
dpm
DMBA
D & e
DUB
EDTA
ER
LMP
NADP+
NADPij
PBS
PBSG
PMB
17~ -OHSD
RIA
SEM
SHBG
TLe
TRIS
OTHER ABBREVIATIONS
Androgen Receptor
6~-Bromo-1 7f3 -Hydroxy-1 70<-methyl-4oxa-
5~-androstane-3-one
Bovine Serum Albumin
counts per minute
coefficient of variation
corticosteroid binding globulin
Dextran coated charcoal
disintegrations per minute
7,12-dimethylbenz(a)anthracene
dilatation and curettage
Dysfunctional uterine bleeding
Ethylenediaminotetra-acetic acid
Oestrogen receptor
Last menstrual period
Nicotinamide-adenine dinucleotide phosphate
Reduced nicotinamide adenine dinucleotide
phosphate
Phosphate-buffered saline
Phosphate buffered saline containing 0.1%
(w/v) gelatine
Post menopausal bleeding
17~-hydroxy steroid dehydrogenase
Radioimmunoassay
Standard error of mean
Sex hormone binding globulin
thin layer chromatography
2-Amino-2-(hydroxymethyl)propane-1,3-diol
SUMMARY
The role of C19 steroids in the human endometrium is at
present unclear. In order to gain an insight into their
action, radioimmunoassay procedures were developed which
had sufficient specificity and accuracy to measure
testosterone, Soc-DHT, oestradiol, progesterone and
androstenedione in endometrial samples. Amounts of
androstenedione were greater (range 1.2-20.8 ng/mg
tissue) than other steroids. Samples were obtained from
patients presenting with a variety of conditions:
subfertility, postmenopausal bleeding, dysfunctional
uterine bleeding and abdominal pain. Patients admitted
for sterilisation were used as normal controls.
A significant positive correlation (r = 0.80) was found
between the levels of testosterone and 5D' -DHT measured
in the same tissue which suggests the presence of a 5~-
reductase enzyme. No relationship was observed in
tissue steroid concentration and age of the patients.
Steroid concentrations were found to be high in tissues
obtained from patients with endometrial carcinomas
whereas progesterone concentration being low in
subfertiles.
The oestrogen, progesterone and androgen receptor levels
of endometrial tissues from subfertile women were also
determined using the DCC technique and not the procedure
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based on protamine sulphate precipitation since
endometrial tissue available was very small. No
correlation was found between receptor binding sites and
day of cycle for any of the three steroids analysed;
nor was there any correlation between age and receptor
binding sites. A cyclic variation followed by normal
women was seen in the oestrogen and progesterone
receptor concentrations in the menstrual cycle. Such a
variation was also observed in subfertile women on
clomiphene citrate therapy.
It is concluded that normal endometrium contains
measurable quantities of androgens and that a receptor
for 5«-DHT is present. The difference in steroid
concentrations between normal and pathological states
suggest that C19 steroids may be induced in the
development of abnormalities.
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GENERAL INTRODUCTION
The intracellular concentrations of steroids and steroid
receptor proteins are the two essential factors that
control the extent of the hormonal actions in target
cells. Human endometrium is an ideal target tissue in
which to study the interrelated hormonal effects that
occur intracellularly. The length of the menstrual
cycle and the availability of the endometrial tissue at
the various stages provide a natural source to observe
the hormonal regulation of the receptor level.
The mammalian uterus is a highly specialised
fibromuscular and secretory organ by which the female
accommodates growth and differentiation of one or more
concepti within her body. The myometrium is elastic;
its contractile properties are responsive to a variety
of hormonal regulators secreted both locally and
distally. In contrast, the inner lining of the uterus,
.the endometrium, is a distinctive tissue both in form
and function.
The variation of the level of oestradiol receptor in
target tissue was first reported to occur in human
endometrium when the receptor concentration was measured
at different stages of the menstrual cycle (Tseng and
Gurpide, 1972). It was later confirmed that
progesterone suppresses the synthesis of oestradiol
1
receptor in human endometrium. In addition, the human
endometrium was believed to be the only organ known in
which progesterone exerts an inductive effect on the
17~ -hydroxy steroid dehydrogenase (17P -OHSD) (Tseng
and Gurpide, 1975). The activity of 17P-OHSD controls
the rate of the metabolism of oestradiol to oestrone in
endometrium and therefore its intracellular
concentration. Thus, in addi tion to the level of
circulating steroids, the endometrium generates its own
system for regulating the intracellular steroid
concentration.
More recentiLy , however, a signif icant rela tionship
between 17~-OHSD activity in tissue adjacent to breast
tumours and breast tumour size has been found (Beranek
et al 1986 & James et al 1986 have also found a
significant relationship between 17~ -OHSD activity in
breast tumours and tissue adjacent to the tumours.
These findings suggest that a factor(s) produced by the
tumour· might influence 17(3-OHSD activity. To
investigate this possibility Reed et al have developed
an in vitro system to examine the effect of tumour
homogenates on 17~-OHSD activity in cultured adipose
tissue. James et al (1986) also showed that
progesterone may influence aromatase, and that adrenal
androgens can inhibit 17p-OHSD activity.
In 1983 Sym et al gave evidence that androgens increase
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intracellular receptor concentration through stabilising
existing receptors, and by increasing de gQYQ receptor
synthesis.
Testosterone, androstenedione, DHEA, DHEA-sulphate, DHT
and 3d,17~ -androstanediol are the main circulating
androgens in the normal woman. The most important of
these is testosterone, even though plasma concentrations
of some weaker androgens exceed that of testosterone
(Anderson, 1974).
In normal women, androgens are synthesised and secreted
both by the ovaries and by the adrenals, but extra-
glandular conversion of androgenic precursors make an
equally important contribution to androgen production.
Braithwaite and Jabamon (1983) showed that in the case
of testosterone peripheral conversion from
androstenedione and DHEA accounts for about half of
total testosterone production, and the ovary and
adrenal's contribute approximately a quarter each. In
Table 1 the relative contribution of glandular secretion
and extra-glandular conversion to overall production
rates of the main circulating androgen in normal women
are shown. These figures contrast sharply with the
situation in men, in whom plasma levels of testosterone
are about ten times higher than in women and
approximately 95% of this is derived from testicular
secretion.
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The pathways of androgen synthesis in the ovary and
adrenals are similar. In both sites, precursors derived
from cholesterol form either progesterone or
pregnenolone, from which are produced the 17~ -hydroxy
derivatives, and these in turn are processed to form
androstenedione and DHEA. Each of these compounds may
serve as a precursor for testosterone which may be
formed at intra-glandular or extra-glandular sites
(Figure 1).
TABLE 1
Origin of Androgens in Women
(% total production)
(Jerums & Thomas 1985)
Androgen Plasma1 Ovary Adrenal Extra-glandularnmol.l- conversion
% total production
Testosterone 1.7 25* 20 50 (-A)
5 (-D)
Andros'tenedione 2.4 35* 50 15 (-D)
DHEA 17 25 50 25
DHEA-sulphate 2170 0 70 30
DHT 0 0 80 (-A)
20 (-D)
*
-A = from androstenedione
-D = from DHEA
Ovarian contribution increases near ovulation
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FIGURE 1
Biosynthesis of Androgens
CHOLESTEROL
I
, 20, 22 hydroxylase
desmolase
PREGNENOLONE
17a--/XY1~ ~
l7ctOB PREGNENOLONE PROGESTERONE
I ~
C17, 20 lyase 17 a OB progesterone
~ !
DHEA 3:.._p_-_o_B_SD_~4-ANDROSTENEDIONE
~ AS-4 isomerase J r
microsomal 17 {30BSn . 17[3 OHSD
, J
5-ANDROSTENEDIOL 7TERONE
. Sa - reductase
-:
S-ANDROSTANEDIONE
Sa DET
3~ oasn
3a OBSD
5 a -ANDROSTANE- 3a ,17 i3
- 3a ,17;3 di01
Androgens differ in their specificity for target organs.
For instance, the skin and its appendages respond mainly
to DHT (which is converted locally from testosterone by
5« -reductase) rather than to testosterone (Braithwaite
& Jabamon, 1983). By contrast, testosterone acts
directly in muscle and the weaker androgens,
androstenedione and DHEA act either by peripheral
conversion to testosterone or by direct interaction with
cytoplasmic receptors in androgen-sensitive tissues.
(Braithwaite & Jabamon, 1983.)
In plasma, DHT, testosterone and androstenedione are
carried bound predominantly to SHBG. SHBG levels are
increased by oestrogens and decreased by androgens, and
are universally related to the metabolic clearance rate
of testosterone. Thus, raised levels of testosterone
cause a decrease in SHBG levels which increase the
metabolic clearance rate of testosterone in the liver
and also increase tissue exposure to unbound
testosterone (Figure 2). In normal women, about 2% of
circulating testosterone is unbound, 60% is bound to
SHBG, 38% is bound to albumin, and less than 1% is bound
to CBG. (Pardridge, 1981).
Clinical evidence of androgen excess correlates better
with levels of unbound testosterone than with plasma
levels (Rosenfield, 1971) but the measurement of free
testosterone levels is not yet readily available for
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FIGURE 2
Role of SHBG in Androgen Action
PLASMA T ---~ SHBG E---- OTHER ANDROGENS
i 1
MCR T oE----- % FREE ----+ ANDROGEN EFFECTS
(liver)
T = testosterone
SHBG = sex hormone binding globulin
MCR = metabolic clearance rate
(Jerums & Thomas, 1985)
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routine clinical use.
Plasma levels of SHBG also reflect unbound testosterone
levels, and therefore represent an index of the
biological effects of testosterone. According to
Vermeulen et al (1971) it is debatable whether an index
of "free" testosterone adds any more information than
separate measurements of testosterone and SHBG.
Androgen metabolism occurs in the liver, adrenals,
ovary, endometrium and in androgen sensitive tissues,
such as skin, fat and muscle. Five principal enzymes
involved are aromatases, reductases, dehydrogenases and
the conj ugating enzyme glucuronyl transferases and
sulphotransferase (Table 2). The liver is the main site
of androgen conjugation and the resulting glucuronides
and sulphates are essentialiy inactive. The 50<.-
reduction of testosterone to form the more active DHT is
.the most important step in the enzymatic processes
involved in androgen action on the skin. Other enzymes
participate in mediating or modulating androgen effects,
but their role remains to be determined.
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TABLE 2
Androgen Metabolism
(Jerums & Thomas, 1985)
Skin Dihydrotestosterone Androstanediol
Androstenedione Oestrone*
Testosterone Oestradiol*
Liver Androstenedione Androsterone +
aetiocholanolone+
DHEA
Progesterone
17-0H Progesterone
DHEA-sulphate
Pregnanediol
Pregnanetriol
Testosterone
androsterone and
aetiocholanolone
Glucuronide and sulphates
All these steps lead to loss of androgenic function.
* this reaction, controlled by aromatase, also
occurs in adipose tissue and in the ovary.
+ Androsterone and aetiocholanolone (and their
conjugates) are main urinary androgens.
In post-menopausal women there is a dramatic decline in
the circulating levels of oestrogens (Longcope, 1971;
Studd et ~l, 1978) compared to the levels in
reproductive-aged women. That the decrease in
circulating oestrogen levels is not even more pronounced
is in part due to an increase in the rate of peripheral
aromatisation of androgens (Longcope, 1971, 1973 ;
Grodin et aI, 1973). According to Studd et al (1978)
and Abraham & Maroulis (1975), at menopause there is
also a decline in circulating levels of androgens.
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Vermeulen and Verdonck (1978) have shown that these
decreases in androgen levels correlate with the
menopause state.
Androstenedione production has been noted to be lower in
postmenopausal women as compared to premenopausal women
(Studd et ai, 1978; Poortman et ai, 1973; Kirschner et
ai, 1978) but testosterone production has been reported
to be similar in both age groups (Bird et ai, 1978).
Whilst the effects of steroid hormones are relatively
well documepted, their mode of action has only been
elucidated in the last 20 years or so, since radio-
labelled oestradiol only became available in the late
1950s.
Some of ~he earliest work was performed by Jensen and
Jacobson (1962) using [3H]-labelled oestradiol. If the
radio-labelled steroid was administered to immature
rats, it was found that growth responsive tissue (eg
uterus and vagina) continued to incorporate it and to
retain it for longer periods than other tissues (eg
liver, kidney, adrenal or muscle). They also found that
the concentration of oestradiol in the growth-responsive
tissues was greater than in blood, whereas the
concentration in the other tissues mirrored that of
,blood (Figure 3).
10
FIGURE 3
Concentration of radioactivity in rat tissues after
single subcutaneous injection of O.098ug of
6,7,[3H]-oestradiol in O.Srnl saline.
(Jensen and Jacobson, 1962)
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Since then there has been considerable experimentation
in this field, usually using radio-labelled steroid, and
it is now generally accepted that in order to exert
their effect steroid hormones enter the cytoplasm of
target cells where they interact with a receptor. The
resulting receptor-hormone complex then moves into the
nucleus where gene expression is affected and the action
of the hormone is brought about by subsequent increases
in mRNA and protein synthesis.
This whole concept of a 2-step model has been
challenged • . For example, Fleming and Gurpide (1980)
found nuclear ER in normal human endometrium which were
not bound to any hormone. Suggestions that this finding
could be explained by the ER complex translocating to
the nucleus, then dissociating rapidly leaving intact
availabl~ receptor in the nucleus, were refuted by
Sonnenschein et al (1976) who found free nuclear
receptors in cell lines from which oestradiol had been
excluded. King and Greene (1984) performed
immunocytochemical staining by a monoclonal antibody
generated against the ER protein. Specific staining
was found to be confined to the nucleus of all stained
cells, which included human breast tumours and uterus,
rabbit uterus, oviduct, corpus luteum, mammary gland,
pituitary and liver, as well as MCF-7 cell cultures.
,These findings were supported by Welshon et al (1984)
who found that there was a 10 fold reduction in the
12
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I'
receptor titre of enucleated pituitary tumour cells
compared with whole cells and that the missing receptor
was recovered in the nuclear fraction.
The initial entry of steroid hormone into the cytoplasm
through the cell membrane is thought to be passive and
independent of the receptor.
Work by Gurpide and Welch (1969) supported this idea
when they showed that oestradiol, oestrone, testosterone
and androstenedione were taken up equally by
endometrium, and they also found that there were no
saturable mechanisms for oestrogen or androgen lentry
into the tissue.
Initial investigations into the nature of the oestradiol
receptor revealed it to be a protein of sedimentation
coeffiriient 9.5s which interacted with DES but was
unaffected by testosterone and corticosterone (Toft and
Gorski, 1966).
Later investigations (Erdos, 1968) showed that the
receptor had a sedimentation coefficient of 8s in
hypotonic medica, and dissociated to form a 4s binding
subunit to KCl concentrations greater than 0.2mol.1-1.
Investigations of the molecular weight of the 4s form
put it as low as 60,000 (Yamamoto and Alberts, 1972) and
1 3
FIGURE 4
Mode of action of oestradiol
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(Jensen et aI, 1968)
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as high as 80,000 (Notides et al, 1972) depending on the
tonicity of the media used.
Jensen et al (1968) suggested that the cytoplasmic form
of oestradiol receptor complex moved into the nucleus
where it was found as the Ss complex when they observed
that a Ss complex found in the nucleus increased as the
cytoplasmic receptor decreased when oestradiol was
administered. They also showed that the Ss oestradiol
receptor complex required the 8s complex for its
formation.
This concept was strengthened by Shyamala and Gorski
(1969) who confirmed the findings of Jensen et al (1968)
and Clark et al (1973) who demonstrated in vivo
translocation of the oestrogen-receptor complex under
the infiuence of endogenous oestrogen during the
menstrual cycle.
Translocation is temperature-dependent (Jensen et al,
1968) and is unaffected by many metabolic inhibitors, so
is probably not an energy utilising system (Shyamala and
Gorski, 1969).
Many studies have been carried out since the late 1950s
to elucidate the process involved in the uptake and
.retention of androgens by their target cells. Liao and
Fang (1969); Wilson and Glyona (1970), Williams-Ashman
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and Reddi (1972), Liao (1974) and (1975a) have reviewed
the evidence for the existence of a specific mechanism
for retention of active androgens in the responsive
cells from the study of the organ uptake of androgens,
autoradiographic studies, and discovery of the selective
nuclear uptake of DHT in rat ventral prostate.
Pearlman and Pearlman (1961), and Treter and Aakraag
(1969), found that in the rat, while large amounts of
conjugated metabolites exist in blood and liver, the
prostate accumulates unconjugated androgen metabolites.
In 1968a Bruchovsky and Wilson first reported the
ability of the prostate cell nuclei to retain DHT. For
the androgen receptor in the rat ventral prostate a
hypothetical scheme is shown in Figure 5.
In this hypothetical model, the receptor protein (Ro) is
activated by an energy dependent process that is
sensitive to respiratory poisons such as KeN, azide,
dinitrophenol (DNP). The activated receptor (R) then
binds an active androgen such as DHT that may be formed
from a precursor testosterone. The AR complex (DHT.R)
is transformed in a temperature dependence step to a
form that can be retained tightly by nuclear acceptor.
The receptor androgen interaction may modulate the
.production of mRNA and protein necessary for the growth
and function of prostate. Some protein factors may play
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FIGURE 5
A working model for the step involved in
intracellular cycling in AR in target cells
(Liao, 1984)
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a feedback control in regulating the interaction of the
receptor complex with chromatin.
The conversion of testosterone to DHT is carried out by
an NADPH-dependent 5ec -reductase tightly bound to the
outer nuclear membrane of the prostate (Ofner 1968;
Shimazaki et ai, 1972; Moore and Wilson 1972; Nozu and
Tamaoki 1974).
Brook et a..!.(1981) and Liang & Heiss (1981) have
suggested that a reductase inhibitor can suppress the
nuclear uptake of DHT and the growth of the prostate.
In some androgen resistant organs such as kidney and
muscle, where the reductase activity is feeble,
testosterone may act as the active androgen and interact
with an AR that may also bind DHT.
Uterotrophic and anti-uterotrophic effects have been
described in the immature rat uterus after the
administration of androgens (Huggins et al 1954; Edgren
et al 1960; Dorfman et al 1961; Lerner 1964). It has
also been shown that several androgens compete with
oestradiol for its binding to the cytoplasmic ER
(Notides et al 1972; Poortman et al 1975; Watson et al
1977; Davies et al 1977a; Garcia & Rochefort, 1979).
In 1979 Garcia and Rochefort demonstrated that direct
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binding of two tritiated androgens (5~-androstene-3
,g, 17 f3 -diol) and (5~ -androstane-3 P , 17~-diol) to the ER
and compared their binding characteristics with those of
oestradiol.
In the rat ventral prostate, there are at least two
proteins that can bind DHT. At low concentrations, DHT
binding is exclusively to a high affinity (Ka
1011l.mol-1) and low capacity protein (ft -protein). The
complex (complex II) formed can be retained by nuclear
chromatin (Anderson & Liao 1968; Bruchovsky & Wilson,
1968a; Davie~ & Griffiths, 1974; Fang et al 1969 and
Mainwaring 1969). If DHT is present in excess of the
high-affinity binding sites the androgen forms a complex
(complex I) with another low-affinity (107l.mol-1) and
high capacity protein «)( -protein). Whereas the high-
affinity protein binds only active androgens (Fang et
al, 1969, Fang & Liao, 1971), the low affinity protein
also bind.oestradiol, but not glucocorticoids.
Chan & O'Malley (1976, 1978); Bardin & Caterall(1981);
Liao, 1977 and Muldoon (1980) have shown that all
tissues that respond to androgen administration contain
measurable cytosol AR protein. In most studies, cytosol
AR have been found to sediment at 8-10s on sucrose
density gradient centrifugation in low ionic strength
and to exhibit weights (Mr) of 280,000-360,000 (Bullock
& Mainwaring, 1975; Liao 1977; Mainwaring 1969; McLean
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et al 1976 and Norris & Kohler, 1978). Upon exposure to
O.4M KC1, conversion of the receptor to a faster
sedimenting form (4-4.5s) with a Mr of about 100,000 has
been observed (Fang & Liao, 1971; Lea et al 1979; Liao
1977; McLean et al 1976 and Norris & Kohler, 1978). In
1976 Wilson & French showed that these two forms of the
cytosol receptor seem to be in equilibrium but whether
the longer entities derive from self-association of the
smaller components, or form a mixed aggregation of
receptor and non-receptor proteins, is currently
unknown. Liao (1977), Rennie et al (1977) and Wilson &
French (1979); have reported that even though the
nuclear AR seems to originate from the cytoplasmic
receptor, the physical chemical characteristics of these
two proteins are dissimilar in many studies. For
instance, cytosol AR sediments somewhat faster (4-4.5s)
than the nuclear receptor protein (3-3.5s) in the
presence of 0.4M KC1. This difference may have resulted
from in vi!Eo proteolytic cleavage of the latter
protein, because a longer receptor was observed in the
presence of the protease inhibitor, di-isopropylfluoro-
phosphate by Wilson & French (1979). In addition to the
nuclear receptor, the cytosol AR is also subject to
extensive proteolytic degradation in a variety of
tissues, if analysed in vitro without any protective
agents.
The fact that AR structure is currently so poorly
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understood originates from difficulties encountered in
its extensive purification. Few studies on the
purification of AR have been reported (Bruchovsky et al
1981; Chang et al 1982; Foeken et al 1982; Hu et al
1975; Ichii, 1975; Mainwaring & Mangan, 1973 and
Rennie et al 1977).
Chang et al (1982) achieved only a modest purification
in all but one of these attempts. In that study,
cytoplasm AR was purified 540,000-foid from steer
seminal vesicle and was shown to migrate as a single
protein band w~th a Mr of 60,000 on sodiumdodecylsulfate
polyacrylamide gel electrophoresis. It is not known,
however, whether this molecule represents an intact
oligomer or a proteolytic fragment of the native AR.
,
The biological significance of the receptor interaction
with divalent ions and nucleotides is not clear. As
reviewed by Liao et ai, 1975b, Liao, 1976), metal ions
have been shown to affect the receptors for oestrogens,
mineralocorticoids and progesterone. This may result
from an indirect effect, such as Ca2+ activation of a
protease that may transform the ER complex (8s-5s) to a
form (4.5s) that does not aggregate. The PR complex of
the hen oviduct can interact with ATP rather
specifically. other investigators have speculated that
the "activation" of the glucocorticoid receptor in mouse
fibroblasts or thymus cells may be dependent on an
21
energy supply system or on ATP.
The best evidence for the importance of cytoplasmic AR
in the expression of biological androgen action
originates from studies of testicular feminised (Tfm)
animals which are androgen resistant (Bardin & Caterall
1981; Griffin & Wilson, 1980). Many of the cellular
components of the preputial gland, kidney and pituitary
in Tfm rats exhibit a dose-dependent response to very
large doses of testosterone. Tfm rats have
approximately 10% of the cytosol receptor concentration
found in normal littermates, and its properties seem
normal (Naess et al, 1975).
The biological action of androgens can be antagonised by
a variety of molecules termed antiandrogens. Some of
these antagonistic actions can be related to their more
rapid inhibitory effect on certain nuclear activities in
rat vent.ral prostate including synthesis of RNA
(Anderson et al 1973;
--
Mainwaring et al, 1974a), DNA
(Sufrin & Coffey, 1973) or protein (Liang and Liao
1975). While antiandrogens may act by preventing
androgen synthesis, altering protein binding or
peripheral metabolism of the circulating androgens (Jost
1972), recent studies have also shown that some of the
powerful antiandrogens can act directly on the target
tissues, such as the prostate, to antagonise
intracellular generation of active androgens or the
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binding of androgen by the cellular receptors.
Oestrogens at high concentrations can inhibit the NADPH-
dependent enzymatic reduction of testosterone to DHT by
cell free preparations of rat ventral prostate
(Shimazaki et al 1965a, 1972; Nozu & Tamaoki, 1974). In
the prostate and uterus there are specific oestradiol
binding proteins that are distinguishable from the DHT
receptor protein (Jungblut et al 1971; Armstrong &
Bashirelahi 1974; Van Beurden-Lamers et al 1974). The
ER complex may function independently from the AR and
bring about inhibitory effects. Roy et al (1974)
observed that ~n the liver of adult rats, DHT-binding by
a receptor protein can be inhibited by oestradiol in
vivo and in vitro.
Progesterone does not bind tightly to the DHT-receptor
protein of rat ventral prostate, but at high
concentrations it does inhibit receptor binding of DHT
(Fang et al, 1969; Fang & Liao 1971). Progesterone and
many weak androgens reduce, by substrate competition,
the formation of DHT from testosterone by the same
~nzyme (Voight et aI, 1970). These steroids may,
therefore, decrease the DHT concentration in the target
cell.
Cyproterone and its 170< -aceta te are potent synthetic
antiandrogens (Figure 6) and have been shown to inhibit
nuclear retention and receptor binding of DHT in the rat
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FIGURE 6
Chemical structures of major antiandrogens
Cyproterone -
17 Cc! -acetate
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ventral prostate and seminal vesicles in vivo and in
vitro (Fang et aI, 1969, Fang & Liao, 1971; Stern and
Eisenfeld 1969; Geller et al 1969; Geller and McCoy
1974). Similar observations have been made for other
antiandrogens such as R-2956, (Baulieu and Jung, 1970),
BOMT (Margan and Mainwaring, 1972) and flutamide (Peets
et al 1974; Liao et aI, 1974; Mainwaring et al 1974b).
Liao et al (1974) showed that antiandrogens have their
gross geometric structure very similar to that of DHT
and they may indeed act by competing with androgens for
receptor binding.
In the early 1960a the experimental exploration of the
hormone-gene theory was initiated when the molecular
processes of gene expression in terms of RNA and protein
synthesis began to be elucidated (Williams-Ashman,
1965)• In this area one of the earliest biochemical
findings was the demonstration that ribosomes isolated
from the rat ventral prostate injected with testosterone
are more effective than those from the control castrates
in incorporating amino acids into proteins and that this
difference is apparently due to the quantities of mRNA
associated with ribosomes (Liao and Williams-Ashman,
1962) and cell nuclei (Liao, 1965).
Jensen et al (1974) and Liao et al (1975b) have reported
that steroid hormones alone or with receptor
preparations can stimulate RNA synthesis in certain
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cell-free systems. One of the earliest claims for
androgens was made by Lukacs and Sekeris (1967) who
reported that testosterone and cortisol at high
concentrations were capable of stimulating (by 10%) the
RNA synthesis of isolated liver-cell nuclei.
Bashirelahi and Ville (1970) also claimed that in the
absence of added cytoplasmic protein, DHT, but not
testosterone, could stimulate the incorpora tion of
radioactive nucleosides into RNA fractions by cell
nuclei of rat ventral prostate.
Davies & Griffiths (1974) reported that the isolated
DHT-receptor complex can stimulate prostate chromatin-
dependent RNA polymerase (I and II) activity. Hu et al
--
(1975) also reported that the receptor complex can
stimulate the synthesis of RNA on the purified prostate
DNA by an ~-amanitin sensitive calf thymus RNA
polymerase (II).'
The fact that ~any steroid hormones can selectively
increase the production of specific proteins or enzymes
in target-cells has often been considered as evidence
that these hormones act on specific genes.
There are also indications that the initiation process
involved in the protein synthesis is under the control
of androgen (Figure 7). The effect of castration and
androgen injection on the ability of the prostate
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FIGURE 7
Initiation steps involved in proteins synthesis
in the prostate.
(Liao, 1977)
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cytosol proteins to support the binding of
methionyl-tRNAf (the IF activity) to the prostate
ribosomal particles was studied by Liao (1977). It was
found that the cytosol IF activity is reduced within
hours after castration. This loss is prevented by the
intraperitoneal injection of a relatively large dose of
DHT or testosterone, which actually enhances the
activity to a level higher than that seen in the
activity to a level higher than that seen in the normal
animals. More recent studies have revealed that the
prostate cytosol contains certain types of activators as
well as inhibitors for the IF activity (Liang and Liao,
1976; Hung et al, 1976).
--.
Possible roles of these
factors in the androgen response are being investigated.
In vitro (Ruh et al, 1975; Schmidt et al, 1976) and in
vivo (Rochefort & Garcia, 1976; Garcia & Rochefort,
1977; Schmidt' & Katzenellenbogen, 1979) binding of
androgens to specific AR and its subsequent
translocation to the cell nucleus have been observed in
the immature rat uterus, in DMBA induced mammary cancer
of the rat (Garcia & Rochefort, 1978; Nicholson et al,
1978) and in mammary cancer cell lines in culture (Zava
et al, 1979). Recently it has been shown that AR binds
selectively to the C3(1) gene adjacent to the promoter
between nucleotides -225 and +80 and within the first
intervening sequence of the gene (Perry et al 1985;
Rushmere et al 1987). Parker et al (1988) have
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characterised genes in mouse ventral prostate whose
expression is stimulated by testosterone (Mills et al
1987) one of which, encoding a secretory protease
inhibitor, has been cloned.
Mukherjee (1972) and Mukherjee and Chakravarty (1974)
reported a potent positive luteotrophic effect of
testosterone and DHEA in rats as well as the human.
Experiments by Chakravarty and Mukherjee (1977) also
suggest that androgens help to maintain structural and
functional integrity of the corpus luteum. Androgens
therefore preserve and stimulate the corpus luteum to
produce more prog~sterone necessary to build up an
adequate secretory endometrium and thus prepare the bed
for the fertilised ovum to be implanted. Further it
appears (Mukherjee, 1972) that androgens not only exert
a luteotrophic effect in the postovulatory phase, but
also antagonise the possible luteolytic activity of
progesterone-prostaglandin complex. Androgen appears to
be responsible for maintenance of corpus luteum from the
time of fertilisation until the time of placentation.
The therapeutic effect of testosterone in the treatment
of infertility associated with inadequate luteal phase
has been corroborated by success (Chakravaty &
Mukherjee, 1977).
In 1973 Grodin et al and Poortman et al established that
most of .the oestrone production in postmenopausal women
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is derived from peripheral conversion of circulating
androstenedione to oestradiol. Siiteri and MacDonald
(1973) found in obese patients with endometrial
hyperplasia or carcinoma, an excessive conversion of
androstenedione to oestrone resulting in increasing
oestrone. Rizkalla et al (1975) have also found a high
correlation of androstenedione to oestrone conversion
with endometrial cancer. Sall and Calanog (1973) found
a significant decrease in the androsterone excretion in
cancer patients. The excretion of aetiocholanolone and
DHEA was also diminished. Calanog et al (1976) found
that the conversion of testosterone to androstenedione
was significantly decreased in patients with endometrial
cancer; the level of testosterone, its metaboli te
clearance rate and production rate appeared to be
normal. In addition Judd et al (1974a) found normal
circulating levels of testosterone and androstenedione
in endometrial' cancer patients. As DHEA and DHEA-
sulphate are the most prominent C19 steroids produced by
the adrenal cor.tex, it is probable that the decreased
excretion of androgen metabolites change on metabolism
of these precursors.
Rochefort and Garcia (1976) and Garcia and Rochefort
(1977) showed that androgenic hormones can influence the
nuclear accumulation of the cytosol ER in rat uterine
tissue.
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The hypothesis in Figure 8 shows that a decreased level
of those inhibitors due to a decreased production rate
of its precursors will result in an enhanced oestrogenic
activity at the cellular level without an increased
level of circulating oestrogens.
The synthetic radiolabelled androgen R1881 binds to AR
with high affinity, but does not bind to SHBG nor is it
enzymatically converted to less active derivatives
(Bonne & Raynaud, 1975). However, R1881 binds to PR as
well as AR in tissues such as hypertrophic human
prostate (Cowan et al, 1977), as well as endometrial
carcinoma (Kato et al, 1982). Tritiated R1881 binding
to the cytosol of highly differentiated endometrial
carcinoma consists of three components:
1. high affinity low capacity androgen binding
components (ARs);
2. progestin receptors;
3. non-specific androgen binding components
(Kato et al, 1982)
Androgen exerts a direct effect on the endometrial cell,
possibly through its interaction with the AR. Highly-
diffe.rentiated endometrial carcinomas contain much
greater amounts of the AR than do moderately and poorly
differentiated tumours (Friberg et al, 1978). Since the
concentration of oestrogens and progesterone receptors
are lower in moderately and poorly differentiated
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FIGURE 8
A scheme summarising the postulated hypothesis.
The major source of androgens after the menopause
is the adrenal cortex. Androstenedione (A) is
metabolised to mainly androsterone (andro) and
aetiocholanolone (aetio), but can also be
aromatised to oestrone (E1) both in adipose tissue
and in muscle. This peripheral conversLon of
adrenal androgen is the main source of oestrogens
after the menopause. The ovarian contribution to
the production of androstenedione is about 30%.
DHEA and DHEA-sulphate are. mainly adreno-cortical
secretory products which are metabolised to 5-
androstene-3 fl, 17f> -diol (Adiol) and other
compounds. Adiol is a potent inhibitor of the
binding of oestrone (E1) as well as oestradiol (E2)
to the cytoplasm ER. It is still unsolved whether
oestrone is biologically active by itself in human
tissue or if it must be metabolised extra-or intra-
cellularly to oestradiol before it has any
biological effect. This scheme is an extensive
modification of that proposed by Siiteri et al
(1974).
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endometrial carcinomas than highly differentiated
tumours (Janne et al, 1979; MacLaughlin & Richardson,
1978; lviartinet al, 1979; McCarthy et al, 1980; Young
et al, 1976), the former tumours would appear to be
less responsive to major sex steroid hormones such as
oestrogen, progestin and androgen than the latter ones.
A study by Englebienne (1986) on trophoblastic
androgen-binding protein (t-ABP) from serum of patients
with hydatidiform mole indicated that T-ABP behaves
similarly to cytoplasmic AR binding sites of the rat
prostate. By observing the uptake of [3H]DHT in the
human endometrium Muechler's (1987) observations
indicated that androgen binding protein in the human
uterus has the characteristics of the AR.
Ikegami et al (1986) showed by competitive binding
sites that danazol binds to PR and AR, but not to ER of
uterine adenocarcinomas• Thus indicating that danazol
.has sLqnLf Lcarrt;growth inhibi tory effect on human
endometrial adenocarcinoma· cells, possibly through PR
in cells.
Finally, nuclear magnetic resonance signals have shown
a correlation with relative binding affinities to the
PR and with the progestogen/androgen relative binding
ratios (Hopper & Hammann, 1987).
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The present study was undertaken to investigate the
concentration of testosterone, 5~ -DHT, oestradiol,
progesterone and androstenedione in endometrial tissues
obtained from patients admitted to the hospital for D &
C for complaints of PMB, DUB, subfertility and
abdominal pain. Concentrations of androstenedione,
testosterone and 5~ -DHT were measured particularly
because they can interact with both androgen and
oestrogen receptors, and their production in situ make
it difficult to define their biological significance at
the cellular level. Androstenedione and testosterone
are precursors of oestrogen, thus they may contribute
to the above complaints. Furthermore, it is thought
necessary to determine the tissue concentration of
oestradiol and progesterone to assess the biological
significance of androgens in relation to oestrogens in
PMB, DUB, subfertility and abdominal pain.
The ER, PR and AR levels were measured in primary and
secondary subfe.rtility to gain insight into androgen
action and the relationship of C19-steroids to normal
and abnormal endometrial tissue.
An attempt was made to set a procedure for measuring
5~ -reductase enzyme activity in human endometrium.
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MATERIALS AND METHODS
MATERIALS
1. TISSUES
a) Patients and tissue collection
All patients were women admi tted to the City
Hospital and University Hospital, Nottingham for
investigation procedures for subfertility (usually
dye laparoscopies) and for abnormal bleeding.
Endometrial samples were obtained by curettage and
then stored in a dry container at -20oC.
b) Plasma Samples
Blood was collected into EDTA containing tubes
from the vein of the peripheral arm immediately
prior to the operation. After centrifugation,
plasma was stored at -20oC.
2 • CHEMICALS
a) Solvents.
Ethanol (AR) was obtained from Burroughs England;
Ac~tone from May and Baker Ltd., Dagenham,
England, Dichloromethane, hexane and ethylacetate
from Fisons plc, Loughborough, England.
b) Reagents
i) the following reagents were purchased from
Sigma (Lon) Chemicals Co. Ltd., Surrey:
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Monothioglycerol
Protamine sulphate
Dextran T70
Bovine Serum Albumin
Folin Ciocalteu's Phenol Reagent
Sodium tartrate
Activated charcoal
Cytochrome c
NADPH
ii) the following reagents were purchased from
Fisons plc, Loughborough, England:
Gelatine
Copper sulphate
EDTA
di-Sodiumhydrogen orthrophosphate dihydrate
Magnesium chloride
Magnesium sulphate
Potassium chloride
iii) the following reagents were purchased from
May and Baker Ltd., Dagenham, England:
Sodium dihydrogen phosphate
Sodiumhydroxide pellets
Sucrose
iv) the following reagents were obtained from BDH
Chemicals Ltd., Poole:
Dodecamolybdophosphoric acid
Sodium chloride
Sodium carbonate
Buffer tablets pH 7.0 and pH 9.2
TRIS was obtained from East Anglia Chems, Suffolk
and Glycerine from Hills Pharmaceuticals Ltd.
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c) Radioinert Steroids
The following radioinert steroids were purchased
from Sigma (Lon) Chern. Co., Poole, Dorset:
Oestradiol
Testosterone
5oc-DHT
Progesterone
Androstenedione
Androstanedione
Cortisol
DES
The following were obtained from NEN (Dupont) UK
Ltd., Hertfordshire, England:
R1881 (Methyltrienolone)
R5020 (Promegestone)
d) Radiolabelled Compounds
The following radioactively labelled steroids were
Buckinghamshire, England.
purchased from Amersham International pIc,
Steroid
[2,4,6,7-3H4] Oestradiol
[1,2,6,7-3H4J Testosterone
[.1,2,4,5,6,7-3H6J5OC-DHT
[1,2,6,7-3H4J Progesterone
[1,2,6,7-3H4] Androstenedione
[4_14C] Androst-4-ene-3,17-dione
[4_14CJ5«-dihydrotestosterone
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Specific
Radioactivity
99 Ci/mmol
81 Ci/mmol
148 Ci/mmol
91 Ci/mmol
83 Ci/mmol
59 Ci/mmol
57 Ci/mmol
The following steroids were purchased from NEN
(Dupont) UK Ltd., Hertfordshire, England:
[3H]R1881
[3H]RS020
87 Ci/mmol
87 Ci/mmol
e) Scintillation fluid (Scintillator 199) was
purchased from United Technologies Packard and
Disposable polyethylene scintillation counting
vials from NEN, Dupont UK Ltd., Hertfordshire,
England.
f) Antisera
The following antisera were purchased from
Steranti Research Ltd., London Road, st. Albans,
Hertforshire, England:
Anti-Testosterone-3-(CMO) BSA
Anti_;'Soc-DHT-3-(CMO)BSA
Anti-17-0estradiol-6-(CMO) BSA
Anti-Androstenedione 7~-Carboethylthioether-
ovalbumin (sheep»
Anti-progesterone 11~-hemisuccinate-BSA was a free gift
from Professor K. Griffiths, Tenovus Institute for
Cancer Research, Cardiff, UK.
3 • EQUIPMENT
a ) Glassware
Glassware was decontaminated by soaking in
Quadralene 3000 overnight followed by thorough
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rinsing in tap water and deionised water before
drying in a hot-air oven. Disposable
polypropylene tubes were used for RIA and receptor
assays.
b) Automatic Pipettes
Automatic pipettes with disposable polypropylene
tips were used for repeated sampling of microlitre
quantities of fluid. Adjustable Finnpipette (200-
1000pl) was purchased from Jencons Scientific Ltd;
Hemel Hempstead, Herts. Oxford pipettes (1Ou L,
50}.l1,100}.l1,200pl, 1000}.l1)were obtained from
Boehringer Corporation (Lon) Ltd., Lewes, East
Sussex.
c) pH stick was purchased from Gallenkamp,
Loughborough, England and was calibrated weekly
with buffet tablets.
d) Pre-coated. silica gel/UV254 plastic sheets (20 x
20cm, 0.25mm thick) were obtained from Camlab,
Cambridge.
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BUFFERED SOLUTIONS AND SUSPENSIONS USED IN
RIA AND RECEPTOR ASSAYS
a) Phosphate-buffered saline (PBS)
A 0.01M sodium phosphate buffer (pH 7.4) with
0.15M sodium chloride was prepared weekly by
dissolving NaH2P04.2H20 (0.78g), Na2HP04.12H20
(0.890g), sodium chloride (17.532g) in distilled
water to a total volume of 2 litres.
b) Phosphate-buffered saline with gelatin (PBSG)
Gelatin was dissolved in PBS with heating and
stirring to form a 0.1% (w/v) solution, (PBSG),
which was used 'for the various radioimmunoassays.
c) Dextran-coated charcoal suspension (DCC-RIA)
Commercial charcoal was clean and removal of fines
was unnece~sary. Suspensions were prepared by
making a solution of Dextran T-70 0.02% or 0.05%
(w/v) in PBSG at 4oC, followed by addition of
Norit A charcoal (0.2% or 0.5% w/v, respectively)
and stirring for a minimum of 2 hours at 4oC.
Suspensions were stored at 40C and stirred for a
minimum of 20 min, before use and continuously at
40C while aliquoting. The 0.2% (w/v), charcoal
suspension was used for androstenedione while the
0.5% (w/v), suspension was used for testosterone,
5~-DHT, oestradiol and progesterone RIA.
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d) Buffer solution and suspension used in receptor
assay
TRIS buffer - 10mM TRIS-HCl, pH7.4,
1.5mM EDTA, 20% glycerol (v/v)
containing
and 1ml
monothioglycerol
e) Dextran-coated charcoal suspension used in
oestradiol (DCC-ER), progesterone (DCC-PR) and
androgen (R1881) (DCC-AR), receptor assays
DCC suspension (0.7% charcoal, 0.05% dextran, 0.1%
gelatin) was prepared by dissolving 19 gelatin in
200ml of 10mM TRIS buffer pH7.4. 40ml of this
0.5% gelatin splution were used to dissolve 100mg
dextran and 1.4g Norit A charcoal was added with
stirring. The volume was made up to 200ml with
10mM TRIS-Hel buffer pH7.4 and the Dee suspension
was stirred for 1 hour at 4oC.
The ice-cold suspension was stirred continuously
during subsequent sampling.
Preparation of Kiliani1s reagent
To 20ml of concentrated sulphuric acid 92ml of
distilled H20 were added and to 32.2g of sodium
dichromate 70ml of distilled water were added. After
cooling, these mixtures were combined together to make
Kiliani's reagent and 10ml of acetone was added.
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Preparation of [14CJ 5«-androstanedione
1OuL of [14C] 50(-DHT were taken and the solvent was
evaporated using a stream of nitrogen. SOOpl of
Kiliani's Reagent was then added and the solution was
left for 20min at room temperature. The reaction was
terminated by the addition of 2ml of distilled water
and the steroid material was extracted twice using
ethyl acetate (2 x Sml).
Following this, 0.1mg of unlabelled carrier steroid was
added and then the ethyl acetate was evaporated using a
stream of nitrogen. The residues were separated using
TLC carried out. on silica coated plates with
fluorescence at 2S4nm and the plates were run in a
solvent containing cyclohexane:
v/v)•
ethy laceta te (1:1
Non-radiolabelled marker steroid mixture (1mg.ml-1
androstenedione and 1mg .ml-1 Sex-androstanedione) were
~potted on the plates on either side of the incubation
residues, and a control sample of ethanol alone was run
on the plate.
The plates were run in an airtight tank for
approximately 40 min., at 170C and then the locations
of the marker steroids on the chromatograms were
visualised after spraying with a solution of
dodecamolybdophosphoric acid (10%) in ethanol followed
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by heating. The positions of androstenedione on the
plate, both for the controls and the incubation
extracts, were also visualised by illumination with an
ultra-violet lamp.
The radiolabelled steroid was eluted with 1ml of
methanol and 5ml of ethanol were added to the residual
[14C]-5~-androstanedione.
The radioactivity of the [14C]5~-androstanedione
solution was determined by counting an aliquot of the
product solution using a 1211 Minibeta liquid
scintillation counter (LKB Wallac).
Definitions of Patients
Controls: patients with no gynaecological
complaints, but admitteq to hospital for
requested sterilisation. These patients
had previously had at least one
pregnancy. (Number of controls 45.)
PMB: patients complaining of post-menopausal
bleeding. All tissue samples taken from
these patients were subsequently
confirmed to be endometrial cancers.
(Number of PMB 22.)
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DUB: patients diagnosed as suffering from
dysfunctional uterine bleeding and were
not necessarily fertile. (Number of DUB
34. )
Abdominal
pain:
patients admitted for complaints of
pain in the abdomen. This is a cohesive
group since there was no abnormal
diagnosis after laparoscopy. (Number of
abdominal pain 19.)
Primary subfertility
1. Had never been,pregnant.
2. Consort's semen had been analysed.
3. Normal pelvis observed at laparoscopy.
4. Fallopian tubes were patent.
5. There was evidence of ovulation at laparoscopy.
6. Had appropriate serum progesterone and/or
oestradiol levels. (Number of primary subfertiles
26. )
Secondary subfertility
Patien~s investigated for subfertility for at least 12
months, but who had previously had at least one
pregnancy. (Number of secondary subfertiles 23.)
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METHODS
A RIA
I TITRATION CURVES
a) Testosterone, ~-DHT and Oestradiol
The preparation of antisera dilution curves was
obtained using an assay system initially based
upon that of Hillier ei ~l (1973). Serial
dilutions of antiserum within a range of 1/100 to
1/10 were prepared in PBSG and an aliquot (100pl)
of each dispensed into two sets of assay tubes.
Radioligand solution (100pl) was added to one set
of tubes and radioligand solution containing 500pg
of corresponding unlabelled steroid (1OOpl) into
the other set. Two tubes were set aside to check
total radioligand added per tube (total counts)
and another two "blank" tubes to check the
.
efficiency of absorption of free steroid by the
dextran coated charcoal suspension. All tubes
wer~ mixed on a vortex mixer and incubated at 40C
overnight. Following incubation, free steroid was
removed by addition of 1ml of ice-cold Dee
suspension to all tubes except "totals" which
received 1ml of PBSG. The contents were mixed,
incubated at 40C for 15 minutes and then
centrifuged at 2000g in a refrigerated centrifuge
for 10 minutes. Radioactivity was measured in the
supernatant.
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Antiserum dilution curves were drawn by plotting %
total radioactivity bound versus antiserum
dilution, for both sets of tubes containing
radioligand in the presence and absence of
unlabelled steroid. The concentration of
antiserum used was that which bound between 17%
and 70% for T, 18 - 40% for 5~ -DHT and 11.5% and
60% for E2 total radioactivity and showed the
greatest displacement by radioinert steroid
(Figure 9a).
b) Progesterone
A similar procedure was used with exception of a
range of dilutions of 1/500 to 1/4000.
Radioligand solution (100pl) was added to one set
of tubes and radioligand solution containing 1ng
of corresponding unlabelled steroid (1OOpl) into
the other set (Figure 9b).
The concentration of antiserum used was that which
bound between 10 and 4.0%total radioactivity and
showed the greatest displacement by radioinert
steroid [Figure ge).
c) Androstenedione
Serial dilutions of antiserum with a range of
1/12000 to 1/192000 were prepared in PBSG and an
aliquot (100pl) of each dispensed into two sets of
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FIGURE 9a
Titration curve for anti-testosterone serum
The anti-testosterone serum was diluted in PBSG and
dilutions were incubated with [3H] testosterone
alone (0) or together with labelled testosterone
( 50 Opg) (.).
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FIGURE 9b
Titration curve for anti-~-DHT serum
The anti-50(. -DHT serum was diluted in PBSG and the
dilutions were incubated with [3] 50<.-DHT alone (6.)
or together with unlabelled 50( -DHT (500pg) (A).
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FIGURE 9c
Tritration curve for anti-oestradiol serum
The anti-oestradiol serum was diluted in PBSGand
the dilutions were incubated with [3H] oestradiol
alone (0) or together with unlabelled oestradiol
( 30 0 pg ) (.).
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FIGURE 9d
Titration curve for anti-progesterone serum
The anti-progesterone serum was diluted in PBSG and
the dilutions were incubated with [3H] progesterone
alone (v) or together with unlabelled progesterone
( 500 pg) (.).
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FIGURE ge
Titration curve for anti-androstenedione serum
The anti-androstenedione serum was diluted in PBSG
and the dilutions incubated with
[3H]androstenedione alone or (~ ) together with
unlabelled androstenedione (1000pg) (A).
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dilution assay tubes.
Radioligand solution (1OOpl) was added to one set of
tubes and radioligand solution containing 1000pg of
corresponding unlabelled steroid (100pl) into the other
set (Figure 9d).
The concentration of antiserum used was that which
bound between 15 and 45% total radioactivity and showed
the greatest displacement by radioinert steroid (Figure
ge) •
II STANDARD CURVES,
a) Testosterone and 5« -DHT
Standards to cover the range of 0-500pg were
established by successive dilutions of a stock
solution (500pg/100pl) of each steroid. A series
of concentrations were prepared in ethanol, such
that 100pl of the appropriate steroid contained
10,20, 50,' 100, 200, 300 and 500pg steroid.
Aliquots were dispensed into duplicate tubes and
ethanol (100pl) into two zero standard tubes.
Ethanol was evaporated under a stream of nitrogen
in a water ~ath at 250C and the tubes cooled at
40C before addition of the appropriately diluted
antiserum (100pl). After 30 minutes incubation in
ice, the corresponding radioligand solution in
PBSG (100pl) was added~ [38] testosterone 20,000
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FIGURE 10a
Standard curve for testosterone RIA
Anti-testosterone serum (final dilution 1/75) was
used for preparation of standard curve. Each point
represents mean ~2SEM where n = 10.
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FIGURE 10b
standard curve for 5~ -DHT RIA
Anti-5~ -DHT serum (final dilution 1/100) was used
for preparation of standard curve.
represents mean ~2SEM, when n = 10.
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FIGURE 10c
standard curve for oestradiol RIA
Anti-oestradiol serum (final dilution 1/50) was
used for preparation of standard curve. Each point
represents means ±2SEM, where n = 7.
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FIGURE 10d
standard curve for progesterone RIA
Anti-progesterone serum (final dilution 1/1000) was
used for preparation of standard curve. Each point
represents mean ±2SEM, where n = 5.
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FIGURE 10e
Standard curve for androstenedione RIA
Anti-androstenedione serum (final dilution 1/6000)
was used for preparation of standard curves. Each
point represents mean ±2SEM, where n = 5.
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dpm, [3H]5~ -DHT 10,000 dpm.
"Total counts" and "blank" tubes were prepared and
the assay performed as for titration. Standard
curves were prepared by plotting total
radioactivity bound versus steroid mass in each
tube (Figure 10a, b).
b) Oestradiol
A similar procedure was adopted using standards in
the range 0-300 pg and 10,000 dpm in the
radioligand solution (Figure 10c).
c) Progesterone
Standards in the range of 0-500 pg were used with
5,000 dpm in the radioligand solution (Figure
1 Od) •
d) Androstenedione
Standards in the range of 0-1,000 pg were
established with 4,000 dpm in the radioligand
solution (Figure 10e)
III ASSAY PARAMETERS
1. Recovery
The range of recovery from tissues of [3H]-steroid
"internal standards" were: testosterone 35-95%,
50<.-DHT 35-95%, oestradiol 50-84%, progesterone
60-80% and androstenedione 40-70%.
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TABLE 4
INFLUENCE OF TISSUE MASS ON ESTIMATED
STEROID CONCENTRATION
Two separate tissue samples (1Omg and 19m9) from the same
specimen were subjected to the assay procedure and
the concentration of steroids evaluated
Tissue mass T 50(-DHT E2 Prog A
Processed
(mg) ng/mg tissue
10 0.48 0.24 0.01 0.04 1.28
19 0.,52 0.29 0.03 0.01 1.30
T = Testosterone
Sex.-DHT = S«-Dihydrotestosterone
E2 = Oestradiol
Prog = Progesterone
A = androstenedione
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2. Precision
The errors associated with replicate
determinations of two or three tissue homogenates
were determined within a single assay and between
several assays. The·coefficient of variation for
these determinations are listed in Table 3.
3 Assay Specificity
The specificity of the assay for each steroid was
tested by determining steroid content in
increasing amounts of tissue homogenates. Table 4
shows that increasing the tissue sample did not
influence estimate of the steroid
concentration.
The accuracy of each assay was assessed by
determining recovery of each steroid added to
,
tissue homogenates and the results are shown in
Table 5. The data showed that acceptable recovery
of each steroid was achieved.
IV EXTRACTION OF STEROID FOR RIA FROM ENDOMETRIAL
TISSUE
It was impractical to assay all steroids of the
sample at once. Tissue samples were chopped and
random portions were taken for extraction
procedures.
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a) Testosterone and sex -DHT
An accurately weighed amount of tissue (up to
20mg) suspended in 1ml PBSG was homogenised in a
glass-glass homogeniser at 4oC. To 1ml of the
homogenate of steroid internal standard was mixed
thoroughly and incubated at 40C for 30 minutes.
Following incubation the contents were extracted
twice with 3ml acetone: ethanol (1:1 v/v). The
solvent layer was dried under a stream of nitrogen
at 3SoC to a volume of about O.Sml and before re-
extracting with dichloromethane (2 x 3ml) 1ml of
distilled water was added. The contents were
centrifuged at.4oC, for 10 minutes at 2000g. The
organic phase was dried under a stream of nitrogen
and reconstituted in ethanol. The extract (1ml)
was then used to perform RIA for testosterone
and ~-DHT (Figure 11a).
b) Oestradiol and Progesterone
An accurately weighed amount of tissue (up to
20mg) suspended in 2ml PBSG was homogenised in a
glass-glass homogeniser at 4oC. The homogenate
was dispensed in to two test tubes (1ml in each
tube) containing 100ul of radioligand solution
(internal standard) and then to only one tube
radioligand solution containing 300pg/100pl
(oestradiol) and 1ng/100pl (progesterone) of
corresponding unlabelled steroid (100ul) was added
63
and mixed thoroughly and incubated at 40C for 30
minutes. Following incubation the contents were
extracted twice with Sml acetone: ethanol (1:1
v/v). The solvent layer was dried under a stream
of nitrogen at 3SoC to a volume of about O.Sml and
before re-extracting with Sml dichloromethane 1ml
of distilled water was added. The contents were
centrifuged for 10 minutes, at 40C at 2000g. The
organic phase was dried under a stream of nitrogen
and reconstituted in 2ml of ethanol. Oestradiol
and progesterone assays were performed (Figure
11b)•
c) Androstenedione
A similar procedure was used with the exception of
concentration of the radioligand solution
containing the unlabelled steroid (Figure 11c).
B. BINDING ASSAYS
STEROID-BINDING STUDIES IN ENDOMETRIAL TISSUE
Preparation of cytosol ·of endometrial tissue
All stages of the assay were performed at 40C in
order to reduce losses of receptors, unless
otherwise stated. An accurately weighed amount of
tissue (between 10mg and 20mg) was homogenised in
a glass-glass homogeniser in 1 ml of 10mM TRIS-
HC1, pH 7.4 containing 20% (v/v) glycerol, 0.1%
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FIGURE lla
Procedure for the extraction of testosterone and
5~ -DHT from endometrium and their quantitation by
specific radioimmunoassay
Tissue (endometrium)
weighed
homogenised in PBSG buffer
incubated at 4°C, 30 min with
internal standard
discard EXTRACTION
residue ~------ with acetone:ethanol (1:1 v/v) 2x3ml
discard
aqueous
layer
RECONSTITUTE
I
~
Testosterone
RIA
dry solvent layer under N2
add 1ml H20
RE-EXTRACTION
with dichloromethane 2x3ml
centrifuge at 4°C, 10 min, 2000g
dry under N2
IN ETHANOL (1ml )
l
Recovery
1
5 cC. -DHT
RIA
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FIGURE llb
Procedure for the extraction of oestradiol and
progesterone from endometrium and their
quantitation by specific radioimmunoassay
discard
residue
TISSUE (endometrium)
weighed
homogenised in PBSG buffer
incubated with internal standard
and corresponding radioligand
solution containing unlabelled
steroid, at 4oC, 30 min
~----- EXTRACTION
with acetone: ethanol (1:1 v/v) 2 x 5ml
discard
aqueous layer
dry solvent layer under N20
Add 1ml H20
RE-EXTRACTION
with dichloromethane 2 x 5ml
centrifuge at 4oC, 10 min, 2000g
dry under N2
RECONSTITUTE IN 2ML
ETHANOL
.(:
Recovery
~
Recovery'1' d' 1Oestra ~o
RIA
~
Progesterone
RIA
66
FIGURE 11c
Procedure for the extraction of androstenedione and
the quantitation by specific radioimmunoassay
~--------- EXTRACTION
1
with acetone: ethanol (1:1
dry solvent layer under N2
1ml H20
RE-EXTRACTION
with dichloromethane
discard
residue
discard
aqueous layer
TISSUE (endometrium)
weighed
homogenised
incubated with internal standard
and corresponding radioligand
solution (1000pg) containing
unlabelled steroid, at 4oC, 30min
v/v)
add
centrifuge at 4oC, 10 min, 2000g
dry under N2
RECONSTITUTE IN (1ml)
ETHANOL
I· t
Androstenedione RIA
r
Recovery
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(v/v) monothioglycerol and 1 .SmM EDTA. The
homogenates were centrifuged at 100,OOOg for 1
hour and the soluble supernatant (cytosols)
obtained were assayed for oestradiol, progesterone
and androgen binding components.
a) Measurement of oestradiol and progesterone
receptors
For the measurement of oestradiol and progesterone
binding components in endometrial tissues an assay
system based upon that of King et al (1979) was
adopted where an excess of DES was used to correct
for non-specific binding in ER assay. DES has the
advantage over oestradiol in this respect that it
does not bind to SHBG. In the PR assay the
addition of excess cortisol blocked CBG.
Volumes (100ul) of supernatant were incubated with
varying concentrations of [3H] oestradiol
(1nmol.1-1. -10nmol.1-1) or [3H] progesterone
(2nmol.1-1-20nmol.l-1). Parallel incubations
included a 100 fold excess of non-radiolabelled
DES in ER assays or non-radiolabelled progesterone
and cortisol in PR assays to monitor non-specific
binding. Incubations were performed at 40C for 10
hours and the free radiolabelled steroid was
separated from the bound steroid by using DCC-ER
or DCC-PR.
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b)
The above concentration ranges were selected for
the ER and PR assays and satisfactory Scatchard
plots were obtained.
Specific binding was estimated by the difference
in the two series of incubations and the binding
site concentrations and dissociation constant
calculated using a Scatchard plot (Scatchard
1949).
The protein content of the cytosol was determined
by the method of Lowry et al (1951) using BSA as
the standard • . Results are expressed as fmol
steroid bound/mg protein.
Measurement of androgen receptors
The cytosol fraction in duplicate tubes was
incubated at 40C overnight with five levels of
[3H]R1881 (0.22, 0.44, 0.88, 1.76, 3.52 nmol/l) in
ethanol in' the presence of 100 fold excess of
R1881 dissolved in ethanol. Bound and unbound
steroids were separated with DCC technique. DCC-
AA (200J.ll)solution was added to the incubation
mixture, mixed well, and kept at 40C for 15
minutes in a refrigerated centrifuge. Supernatant
(bound fraction) was placed in counting vials, and
counted for radioactivity in a scintillation
counter with an efficiency of 30%.
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Quantitative estimation of specific 5~-DHT binding
protein was carried out using an assay system
initially based upon that of Davies et al (1977b).
After performing some kinetic studies, it was
seen that no protamine sulphate precipitate were
obtained, hence the assay system based upon that
of Kato & Seto (1985) was performed as described
above using synthetic androgen R1881.
C 50( -REDUCTASE ACTIVITY IN HUMAN ENDOMETRIUM
Incubation and assay for 5~-reductase activity
A portion of endometrial tissue (10mg) was minced
and homogenised in 1ml of 0.25M sucrose MgCl
solution using a glass-glass homogeniser at 4oC.
The homogenate was then centrifuged at 700g, 15
min, 4oC. The pellet containing cell debris was
discarded and the supernatant was centrifuged at
70,000g in ~n ultra-centrifuge, 30 min, 4oC. The
pellet containing mitochondria was also discarded
and the supernatant containing microsomes and
lysosomes was further .centrifuged at 100,000g, 60
min, 4oC. The pellet and supernatant were
suspended in 43mmol.l-1TRIS-HCl (pH 7.4) and were
used to measure 50l..-reductaseactivity (Figure 12a,
b) •
The mixture of the tissue homogenate [1,2,6,7-3H]
androst-4-ene 17-dione (3000 dpm), 0.2mg NADPH and
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cytochrome c (4mg) was incubated at 370C in a
water bath for 0, 10, 20 and 30 minutes. A
control with the above contents was also set, with
TRIS-HC1 (pH 7.4) instead of homogenates.
After incubation the enzyme reaction was
terminated with the addition of 2 vol of
dichloromethane and subsequently non-radioactive
authentic carrier steroids (0.1mg androstenedione
and 0.1mg 5~-androstanedione). The steroids were
separated from the incubated samples by the
partition between the aqueous phase and
dichloromethane. The dichloromethane was
evaporated under a stream of nitrogen and then
reconsti tuted in 50ul of ethanol. The steroids
thus obtained were purified by TLC.
Thin laye~ chromatographic separation
TLC was carried out on silica coated plates with
fluorescence at 254nm as described on page 42.
Elution of steroids
The plastic sheets were cut into bands at the
level of androstenedione and 5~-androstanedione
(as indicated by the position of the visualised
marker steroid) and these bands were then cut into
their respective chromatogram areas for the
different incubation extracts with different time
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FIGURE 12a
HOMOGENISATION OF ENDOMETRIAL TISSUE
Endometrial Tissue (10mg)
Ihomogenise tissue in glass-glasshomogeniser in 1ml of sucroseMgC1 solution on ice
Centrifuge
I
t
supernatant
1
ultracentrifuge
70,000g, 30 min, 40C
!
'"
pellet
(cell debris)
pellet
(mitochondria)
4 pellet
(microsomes)
t
supernatant
(microsome, lysosomes)
supernatant .
(cytosol)
1
5Ot - reductase assay
72
FIGURE 12b
5~-REDUCTASE ASSAY
[1,2,6,7-3H]A,NADPH, Cytochrome c ~incubate at
supernatant, or pellet or TRIS· 370C for 0, 10,
20, 30 min
terminate reaction
with 2vols of
dichloromethane
1
separate dichloromethane
from incubation
mixture
1
blow down dichloromethane
under a stream of N2
1
+------ add androstenedione
and androstanedione
carbon markers
Reconstitute steroid
in 5011l ethanol
1
TLC --~) develop plates in -------.+ collect radio-
solvent system activity with
of cychohexane:ethylacetate running 1ml
= 1:1 v/vand methanol with
dodecamolybdophosphoric syringe
acid t
blow down
collected
methanol under
N2 !
count radioactivity
in ~ -counter with
carbon and tritium
quench standards
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periods.
methanol.
The steroids were eluted using 1ml of
The respective pieces of chromatogram
were positioned between the lower end of 2 glass
slides, which were attached above to a syringe by
a rubber band, and the methanol was run from the
syringe through the chromatogram and then
collected in vials.
The radioactivity in the methanol was dried under
a stream of nitrogen and then in 4ml of optiphase,
the radioactivity was counted in a -scintillation
counter.
Correction of results
~ standard curve of optical density (OD) against
concentration was obtained for androstenedione by
measuring the OD of androstenedione solutions of
various corlcentrations(O-20mg/l) (Figure 35).
Using the .standard graph, the concentration of
androstenedione in each incubation extract was
found. Therefore, the % recovery of
androstenedione could be calculated by comparison
of the ratio of androstenedione concentration in
the sample to the concentration of carrier
androstenedione added. The values of % recovery
were then used to correct the results for the
counted radioactivity of androstenedione
74
collections.
A similar correction for 5 0( -androstanedione was
not possible using this procedure as, unlike
androstenedione which absorbs light at 254nm due
to the presence of the 64 double bond, 50( -
androstanedione does not absorb light.
After carrying out this procedure a couple of
times, numerous problems were encountered and
hence this method had to be reassessed because of:
i) measuremept of the OD of the collected sample
in order to calculate % recovery could not be
used to determine the % recovery of 5~ -
androstanedione;
ii) the % recovery of androstenedione was poor.
The assay procedure was modified as follows:
only times 0, 10 and 30 minutes were investigated
in order to study the enzyme.
0.1mg of [14C] labelled androstenedione and [14C]_5
androstanedione were added in place of the non-
radioactive carrier steroids, after the termination of
the incubation reaction and before removal of the
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organic solvent layer: the carbon labelled steroid
served two purposes - as before, they acted as carrier
steroids for the [3H]-androstenedione and [3H]-5~-
androstanedione present in the incubation mixture; in
addition the~-scintillation counter was used to count
both radiolabelled carbon and tritium present in the
final sample collection, and the comparison of 3H:14C
ratios was used for the calculation of % recovery. The
efficiency of counting was approximately 65% for 14C
and 35% for 3H when both isotopes were counted
simultaneously. Conversion of cpm to dpm was
accomplished by using external standards. (See
Appendix 1) Theref?re, the method of measurement of OD
was no longer employed.
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RESULTS
FIGURE 13
Relationship between steroid content and
age of patient
a) Testosterone (ng/mg tissue) levels in human
endometrium.
c)
50< -DHT (ng/mg tissue) levels in human
endometrium.
Oestradiol (ng/mg tissue) levels in human
endometrium.
Progesterone (ng/mg tissue) levels in human
endometrium.
b)
d)
e) Androstenedione (ng/mg tissue)
human endometrium.
levels in
• steroid level in endometrium
(....) dotted line indicates detection limit
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Each point represents the concentration from tissue
of one individual patient
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FIGURE 14
Correlation between steroid content (ng/mg tissue)
measured in the same endometrium tissue
a) Relationship between 5~-DHT and testosterone
b) Relationship between oestradiol and testosterone
c) Relationship between oestradiol and progesterone
Each point represents the concentrations from
tissue of one individual patient
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FIGURE 15
Relationship of testosterone (ng/mg tissue)
in:
Controls (sterilisations)
Subfertiles
PMB
DUB
Abdominal pain
(• • • • • ) dotted line indicates limit of detection
«O.01ng/mg tissue)
Each point represents the concentration from tissue
of one individual patient
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FIGURE 16
Relationship of 50( -DHT (ng /mg tissue) in:
Controls (sterilisations)
Subfertiles
PMB
DUB
Abdominal pain
(• • • • • ) dotted line indicates limit of detection
«O.01ng/mg tissue)
Each point represents the concentration from tissue
of one individual patient
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FIGURE 17
Relationship of oestradiol (ng/mg tissue)
in:
Controls (sterilisations)
Subfertiles
PMB
DUB
Abdominal pain
(• • • • • ) dotted line indicates limit of detection
«O.01ng/mg tissue)
Each point represents the concentration from tissue
of one individual patient
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FIGURE 18
Relationship of progesterone (ng/mg tissue)
in:
Control (sterilisations)
Subfertiles
PMB
DUB
Abdominal pain
(• • • • • ) dotted line indicates limit of detection
«O.01ng/mg tissue)
Each point represents the concentration from tissue
of one individual patient
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FIGURE 19
Relationship between testosterone content (ng/mg
tissue) and day of cycle in cases of:
• Controls
o Subfertili ty
• Abdominal pain
V DUB
(• • • • • ) dotted line indicates detection limit
«O.01ng/mg tissue)
Day of cycle was determined from the date of the
LMP and in each case was confirmed by histological
examination. Each point represents the
concentration from tissue of one individual patient.
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FIGURE 20
Relationship of 5 ex-DHT (ng/mg tissue) and day of
cycle in cases of:
• Controls (sterilisations)
o Subfertili ty
v DUB
• Abdominal pain
(.• • • • ) dotted line indicates limit of detection
«O.01ng/mg tissue)
Day of cycle was determined from the dat,e of the
LMP and in each case was confirmed by histological
examination. Each point represents the
concentration from tissue of one individu~l
patient.
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FIGURE 21
Relationship between oestradiol (ng/mg tissue) and
day of cycle in cases of:
• Controls (sterilisations)
D Subfertility
V DUB
• Abdominal pain
(• • • • • ) dotted line indicates limit of detection
«O.01ng/mg tissue)
Day of cycle was determined from the date of the
LMP and in each case was confirmed by histological
examination. Each point represents the
concentration from tissue of one individual patient.
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FIGURE 22
Relationship between progesterone (ng/mg tissue)
and day of cycle in cases of:
• Controls (sterilisations)
o Subfertility
v DUB
• Abdominal pain
(• • • • • ) dotted line indicates limit of detection
«O.01ng/mg tissue)
Day of cycle was determined from the date of the
LMP and in each case was confirmed by histological
examination. Each point represents the
concentration from tissue of one'individual patient •
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FIGURE 23
Saturation analysis of the binding of [3H]
oestradiol by human endometrial cytosol components
(a) Aliquots (100ul) of endometrial cytosol were
inc ubat ed at 40C for ~{)h wit h va rio us
concentrations of [3H] oestradiol alone (0)
or in the presence of 100-fold excess of
unlabelled (~) After incubation samples were
treated as described in Methods (p 68).
Specific binding ( 0 ) was obtained by
subtracting non-specific binding (6) from
total binding (D).
(b) Specifically bound steroid was analysed
according to Scatchard
Kd = 2.1 x 10-10mol•1-1.
(1949)
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FIGURE 24
Saturation analysis of the binding of [3H]
progesterone by human endometrial cytosol
components
(a) Aliquots (100ul) of endometrial cytosol were
incubated at 40C for 20h with various
concentrations of [3H] progesterone alone
( 0) or in the presence of 100-fold excess of
unlabelled A ). After incubation samples
were treated as described in Methods (p 68).
Specific binding ( 0) was obtained by
subtracting non-specific binding (A) from
total binding (0).
(b) Specifically bound steroid was analysed
according to Scatchard
Kd = 1.4 x 10-9mol.1-1•
(1949)
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FIGURE 25
Saturation analysis of the binding of [3H]R1881 by
human endometrial cytosol components
(a) Aliquots (100ul) of endometrial cytosol were
incubated at 40C for 20h with various
concentrations of [3H]R1881 alone ( 0) or in
the presence of 100-fold excess of unlabelled
( ~ ). After incubation samples were treated
as described in Methods (p 69). Specific
binding (0)was obtained by subtracting non-
specific binding (~) from total binding t o ) .
(b) Specifically bound steroid was analysed
according to Scatchard
Kd = 5.3 x 10-9mol.1-1•
(1949)
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FIGURE 26a,b,c
Relationship between patient age and steroid
"receptor" content in human endometrium taken from
subfertile women
The concentration of steroid "receptors" (ER, PR,
AR) in human endometrium (in cases of primary and
secondary subfertility) measured by saturation
analysis is plotted against patient's age.
(• • • • • ) dotted line indicates limit of detection.
«5fmol/mg protein)
Each point represents the concentration from tLssue
of one individual patient.
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FIGURE 27
steroid receptor binding sites (fmol/mg protein) of
normal women (Controls)
o oestradiol
• progesterone
A androgen (R1881)
(• • • • • ) dotted line indicates limit of detection
«5fmol/mg protein)
Each point represents the concentration from tissue
of one individual patient.
0•
.5
.Cl:I
....
e
Co
•
en
~
-a
E
~
c:
.9
....
C'C
-
....
c: 800Cl:I(.)
c:
0
U
•Cl:I
....
us
•
0 • 0
en
.5 0
-c::s •c:
•as
• 0 0
•
o
5 ------------------------;;~-----~--.-------~--------
Ot:
20 30 40 50
Age (years)
102
FIGURE 28
steroid receptor binding sites (fmol/mg protein)
and day of cycle (normal)
o oestradiol
• progesterone
~ androgen (R1881)
(• • • • • ) dotted line indicates limit of detection
«5fmol/mg protein)
Each point represents the concentration from tissue
of one individual patient.
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FIGURE 29
Oestradiol binding site concentration of:
o controls (sterilisations)
• unexplained primary subfertility
• unexplained secondary subfertility.
(• • • • • ) dotted line indicates limit of detection
«5fmol/mg protein)
Day of cycle was determined from the date of the
LMP and in each case was confirmed by histological
examination. Each point represents the
concentration from tissue of one individual patient.
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FIGURE 30
Progesterone binding site concentration
(fmol/mg protein) in:
o controls (sterilisations)
• unexplained primary subfertility
• unexplained secondary subfertility.
(• • • • • ) dotted line indicates limit of detection
«5fmol/mg protein)
Day of cycle was determined from the date of the
LMP and in each case was confirmed by histological
examination. Each point represents the
concentration from tissue of one individual patient.
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FIGURE 31
R1881 (AR) binding site concentration
(fmol/mg protein) in:
o controls
• unexplained primary subfertility
• unexplained secondary subfertility
(• • • • • ) dotted line indicates detection limit
(5fmol/mg protein)
Day of cycle was determined from the date of the
LMP and in each case was confirmed by histological
examination. Each point represents the
concentration from tissue of one individual patient.
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FIGURE 32a,b,c
ER, PR and AR binding site concentrations of women
with unexplained subfertility plotted against day
of cycle
o On clomiphene citrate (CLOMID)
• Not on clomiphene citrate
(• • • • • ) dotted line indicates detection limit
(Sfmol/mg protein)
Day of cycle was determined from the date of the
LMP and in each case was confirmed by histological
examination. Each point represents the
concentration from tissue of one individual patient.
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FIGURE 33
ER binding sites concentration (fmol/mg protein)
and oestradiol serum concentration in unexplained
subfertiles
o controls
• ,0subfertility
• 20 subfertili ty
Each point represents the concentrations from
tissues of one individual patient.
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FIGURE 34
PR binding site concentration (fmol/mg protein) and
progesterone serum concentrations in unexplained
subfertiles
o Control
• 10 subfertiles
• 20 subfertiles
Each point represents the concentrations from
tissues of one individual patient.
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FIGURE 35
Optical density of androstenedione solutions of
varying concentrations at 254nm
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FIGURE 36
An example of the amount of [3H]4-androstene-3,17-
dione metabolised during the incubation period,
using a control, supernatant and pellet. The
values are corrected for % recovery
o incubating with control
• incubating with supernatant
• incubating with pellet
The rate of production of 5~ -androstane3,17-dione
from 4-androstene-3,17-dione was studied as a
function of time (0, 10, 20, 30 mins).
Approximately 10000dpm [3H] androstenedione were
incubated.
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FIGURE 37
An example of the amounts of [3H]-androstenedione
and metabolised during the incubation periods,
using control, supernatant and pellet at times 10
and 30 min.
The values are corrected for % recovery.
o control
• supernatant
• pellet
The rate of production of S~ -androstane3,17-dione
from 4-androstene-3, 17-dione was studied as a
function of Sime (10 and 30 mins). Approximately
SOOOOdpm [ H) androstenedione were incubated.
M
Cl
-><
50
Ea-and rostanedlone
androstenedione
30
E
0-
-0
10
c~·------------------~o
1 ---i:======~====~10+
-0 10 30
Time of Incubation (mins)
114
FIGURE 38
separation of carrier steroids and the radioactive
profile obtained after TLC of extracts of
endometrial incubations
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DISCUSSION
DISCUSSION
Radioimmunoassays were established to measure
concentrations of testosterone, 5«-DHT, oestradiol,
progesterone and androstenedione. RIAs are essentially
reliable, specific and sensitive enough to detect the
hormones at levels often in picogram per assay tube
range and allow measurement of steroids in small
amounts of tissue. A RIA procedure potentially allows
a greater number of samples to be analysed.
The reliability of an analytical method is given by
precision, accura~y, sensitivity and specificity
(Cekan, 1975) and the RIAs employed in this study were
assessed for all these criteria. Precision of each
assay was established by repeated measurement of
endometrial tissue. The intra- and inter-assay
coefficients of variation in these studies were within
a range of 1.4-14% (Table 3) indicating that the
precision was satisfactory. In various tissues from
humans and rats similar coefficients of variation have
been reported. (Bartsch et al 1980; Wang et al 1977;
Corpechot et al 1977; Verdonck et al 1980 and Barberia
& Thorneycroft 1974).
The accuracy of the present assay which was assessed by
measuring the recovery of each radioinert steroid added
to either tissue homogenate or buffer, was also found
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to be satisfactory with recoveries ranging from 55-
113% (Table 5). Another criterion of accuracy was
satisfied by the fact that assessment of "blank
samples" gave values which were indistinguishable from
zero on the standard curve. The specificity and the
accuracy of the assays were further assessed by
assaying extracts from increasing mass of tissue and
were found to be satisfactory (Table 4). The
sensitivity of the assays was assessed by the smallest
amount of steroid standard that differed significantly
from zero. For testosterone this was 3-5pg per assay
tube; for 50(.-DHT5pg per assay tube; for oestradiol
2pg per assay t.ube ; for progesterone 4pg per assay
tube and for androstenedione 10pg per assay tube. From
these and the mass of tissue available concentration of
steroid of less than O.01ng per mg tissue were
considered as indistinguishable from zero.
Oestradiol, testosterone, 51X.-DHT, progesterone and
,androstenedione'were determined in the tissue samples.
Of the 169 samples determined, 147 were from
premenopausal women and 22 were from postmenopausal
women (confirmed histologically as cancer tissue).
Many of the tissue homogenates examined were found to
contain measurable quantities of the steroid. However,
some of the amounts were too low to be read on their
respective standard curves. In addition, some
determinations were not performed because of
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insufficient endometrial tissues for the RIA of all
five steroids.
There was no significant correlation between steroid
content (ng/mg tissue) of endometrial tissues and age
(Figure 13a-e) of the patients for any of the
steroids studied. However, testosterone and 50c-DHT
were higher in younger women compared to oestradiol and
progesterone. Androstenedione levels were
comparatively higher than the rest of the four
steroids. In order to get some information on possible
enzyme activities present in vivo, the relationship
between steroids .measured in the same endometrial
tissues was examined.
A strong correlation (r = 0.80) was found between
testosterone and 5~-DHT content in the endometrial
tissue. (Figure 14a) This high significance between
testosterone and 5~-DHT indicates the activity of a
reductase enzyme. Pollow et al (1975) have shown the
presence of a 5~-reductase in the human endometrium.
Bruchovsky & Wilson (1968a) and Anderson & Liao (1968)
discovered a chromatin-bound steroid 5oc-reductase in
prostatic cell nuclei that catalyses a reduction by
NADPH of the double bond ring A of testosterone to
yie1d 5« -DHT. Shim azaki eta 1 (1965a, 1965b )
indicated that rat ventral prostate also contained a
similarC19-steroid 5~-reductase. In 1971 Frederiken
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& Wilson delineated many properties of 5« -reductase in
rat ventral prostate cell nuclei that catalyses the
NADPH-dependent conversion of testosterone to 5~ -DHT.
No significance (p<0.5) was found between oestradiol
and testosterone content (Figure 14b) in the
endometrial tissue. It has been demonstrated by Tseng
et al (1984b) that more oestrogen is synthesised in
malignant than in normal endometria. Satyaswaroop et
al (1983) have shown that oestrogen promotes the growth
of oestrogen-sensitive endometrial adenocarcinoma.
Thus, aromatase in situ would playa significant factor
in endometrial cancer because of substrate of
aromatase,h4-androgens are available in peripheral
blood in both pre- and postmenopausal women (Judd et al
1974b; Lloyd et al 1971). A relationship between the
two steroids would have been suggested and it may have
been due to the presence of SHBG in the stromal
component; indeed Cowan et al (1976) have reported
·that SHBG may be a constituent of the interstitial
fluid associated with the stroma in human benign
prostate hyperplasia tissue. However, numerous reports
have ,appeared demonstrating the aromatase enzyme
activity in some breast tumour tissue and breast
adipose tissue (Griffiths et al 1972; Varela & Dao
1978); Miller & Forrest 1978; Abul Hajj et al 1979;
Perel etal 1980) . However, these reports show a
considerable variation in conversion rates between
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testosterone and oestradiol, therefore if a possible
relationship was suggested between testosterone and
oestradiol it is unlikely to be due to the presence of
this enzyme system.
Recently Tseng & Bellino (1985) have also demonstrated
that human endometrium contains aromatase and Tseng
1982a, Tseng et al 1982b, Tseng 1984a, and Tseng et al
1984b) have shown that the activity is regulated by
oestrogen and progesterone. No correlation was found
between oestrogen and progesterone in this study.
(Figure 14c). This may be due to the small number of
tissues studied. .Wheater et al (1979) reported that
when the corpus luteum involutes oestrogen and
progesterone fall dramatically and menstruation occurs.
Also continued production of oestradiol and
progesterone maintains the endometrium in a secretory
state which can nourish the blastocyst (Ganong 1983)
(Figure 39) and this lack of correlation may be due to
multiple sources of the steroid.
The relationship between steroid levels and the
pathoLogy of the tissue analysed showed an interesting
pattern (Figures 15-18). The endometrial tissues were
categorised according to the patient's notes as
controls subfertiles, PMB, DUB and abdominal pain. In
general the levels of testosterone and 5« -DHT were
highest in all groups compared to oestradiol and
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progesterone. The level of testosterone, 5o<.-DHT,
oestradiol and progesterone were high in PMB compared
with the other groups. Using Pearson's coefficient
test there is positive significance between
testosterone and 5~-DHT in the controls, DUB and
abdominal pain. (Figure 15-18).
In postmenopausal women, the ovary discontinues its
oestrogen production almost totally although it may
continue to produce androgens (Judd et ai, 1974b;
Greenblatt 1976). The levels of circulating oestradiol
and oestrone are in general lower than those observed
at the follicular .phase of the normal menstrual cycle
in young women (Samolij ik et al 1977) and they
correlate positively with increases in body weight
(Meldrum et ai, 1981).
In the plasma of normal postmenopausal women, levels of
oestrone surpass those of oestradiol in an approximate
.proportion of 2':1to 3:1 (Judd et al 1974b; Samolijik
et al 1977; Longcope 1971;Vermeulen 1976 and Vermeulen
& Verdonck 1978) as occurs in men with comparable
oestr~diol and oestrone values (Samolijik et al 1977).
The concentration of oestrone and the relationship of
oestradiol/androstenedione in castrate women being
similar to values found in normal postmenopausal women
(Vermeulen 1976; Barlow et al 1969; Saez et al 1972).
- -
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The major source of oestrogen in postmenopausal females
is the peripheral formation of oestrone from plasma
androstenedione and not from ovarian or adrenal
secretion (Carlos et al 1984).
DHEA and DHEA-sulphate, despite being the most abundant
androgens circulating in human plasma, are considered
precursors of
aromatisation
little importance in
due to their low
extraglandular
coefficient of
conversion to oestrogen (Maacuso et al 1965; MacDonald
et al 1976).
Oestrone is peripherally produced through aromatisation
of androstenedione and seems to be the main precursor
for extragonadal biosynthesis of oestrogens (Figure
40).
If the steroid hormonal environment is involved in the
causation or in the growth control of endometrial
cancer, minimal changes in the balance between
androgens and oestrogens may be important. It must be
realised that tumour growth is a process of many years
dura~ion and that therefore even small changes may
suffice for a decisive biological effect. Rochefort &
Garcia (1976) and Garcia & Rochefort (1977) have
already shown that androgenic hormones can influence
the nuclear accumulation of the cytosol receptor in rat
uterine tissues. It is not known what action this
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complex has on the chromatin-binding and its
corresponding effect.
Figures 19-22 shows that levels of all four steroids
were measurable in the late proliferative phase though
low, but in the secretory phase the levels of
testosterone and 50<-DHT were higher than those of
oestradiol and progesterone. The complaint of abnormal
uterine bleeding in premenopausal women is one of the
most frequent problems in gynaecology. Al though some
of the cases may be due to an organic cause, over 50%
of the cases are ultimately diagnosed as adult DUB, ie.
a condition of uterine bleeding not associated with
organic cause such as pregnancy, tumour, trauma,
infection or blood dyscrasis. In previous publications
it has been suggested that adult DUB is a result of
hormonal imbalance, namely oestrogen. and progesterone
and that it may be associated with anovulatory cycles
or with ovulatory cycles with corpus luteum effects
(Spellacy 1983; Green 1975 and Spearoff et al 1983).
The relevance of ER and PR measurement in cases with
corpus luteum defects and anovulatory cycles (Levy et
al 1980) found relatively low PR and ER in endometria
of women with anovulatory cycles. Levy et al (1980)
and Pollow et al (1981) also showed that a wide range
of values of both ER and PR may be found in otherwise
normal human endometrium. Levy et al (1980) and
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Gorodeski et al (1984) showed that endometrial PR
levels are sensitive to minor fluctuations of plasma
oestradiol and that ER levels fluctuate less in
magnitude in the course of the cycle. Low PR/ER levels
in endometria of women with adult DUB may represent an
early preclinical state of ovarian insufficiency or an
endometrial end organ defect (Gorodeski et al 1986).
In Figures 21-22 it can be seen that levels of
oestradiol and progesterone are low for the subfertiles
and also there is no correlation between subfertiles
with testosterone, 5o(-DHT, oestradiol and
progesterone (Pearson's Correlation Test).
It is well established that the action of progesterone
in reproductive tissues of different animal species is
influenced by oestrogen and there is simple evidence
that the biolog~cal response of progesterone is carried
out through its receptor which is significantly
enhanced by oestrogen (O'Malley & Means, 1974; Leavitt
et aL, 1977) .
Luteal phase defects (LPD) are thought to represent <4%
of infertility problems. Such defects include
abnormali ties of progesterone action upon endometrium
(Shangold et aI, 1983). McRae et al (1984) have found
that progesterone levels tend to be higher in women
with normal luteal function than those in women wi th
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FIGURE 40
SOURCE OF POSTMENOPAUSAL OESTROGEN
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LPD. In the present study only very few tissues could
give a value for progesterone, but it is convincing
enough that it could be a LPD.
Erickson & Hsueh (1978) have shown that during the
early follicular phase FSH receptors are stimulated on
the granulosa cells and this results in the synthesis
of aromatase enzymes converting thecal androgens to
oestrogens. With the effect of FSH on the granulosa
cells, LH receptors present on the theca cells are
activated and stimulate the synthesis of
androstenedione and testosterone, which diffuse into
the FSH-activated granulosa cells and are converted by
the aromatase system to oestrogen (Ryan et al 1968).
In the late follicular phase of the cycle FSH augmented
by oestrogen stimulate the appearance of LH receptors
on the granulosa cells (Richards et al 1976). A small
amount of progesterone begins to be in the fine tuning
of the developing LH surge. At the time of the LH
surge, there is a small but important mid-cycle rise in
FSH. This FSH surge apparently assumes adequate LH
receptors on the granulosa cells to effect the full
lutenization of these cells, necessary for an adequate
postovulatory or luteal phase of cycle. Thus, it can
be seen that the ability of LH to stimulate granulosa
cell progesterone production during the luteal phase of
the cycle is dependent on the action of FSH and
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oestrogen-stimulating LH receptor protein on the
granulosa cells during follicular phase of the cycle.
These events are summarised in Figure 41.
A positive correlation was found using Pearson's
Coefficient tests between testosterone and 5~ -DHT in
tissues from women with abdominal pain. This
relationship might be due to the activities of a
reductase enzyme. These patients were admitted because
of abdominal pain and the laboratory reports indicated
no abnormal diagnosis with the exception of one patient
with an inactive endometrium. All steroid levels were
measurable and the reason for this complaint is
unknown.
Rogers & Michell (1952) demonstrated that obese women
have a higher incidence of amenorrhoea and ovulation.
Obesity has been associated with different disorders of
-the female repioductive physiology, ego infertility
(Hartz et al 1979) polycystic ovaries (Siiteri &
MacDonald 1973), early menarche and delayed menopause
(Kesley 1974; Sherman et al 1981) menstrual
abnormalities (Hartz et al 1979; Sherman et al 1981),
ego anovulatory cycles, inappropriate luteal phase etc.
All these conditions are considered risk factors for
endometrial cancer (Lucas 1974; Davidson et al 1981).
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In the present study receptors were measured for
oestradiol, progesterone and androgen on endometrial
tissues obtained from women admitted to hospital for
primary subfertility and secondary subfertility. The
majority of steroids act in the same way and this was
believed to be via cytoplasmic receptors which undergo
conformational change on binding a steroid molecule
followed by translocation to the nucleus. This whole
concept has now been challenged following immunological
studies revealing oestrogen receptors (probably
unoccupied) solely in the nucleus (King & Green 1984;
Welshon et al 1984; Sannenschien et al 1976).
The cytoplasmic oestradiol and progesterone receptor
sites were measured by multidose saturation analysis
which employed Dee to separate free and loosely bound
steroid from tightly bound steroid (Maynard & Griffiths
,
1979). No. established procedure, however, was
available for measuring AR sites in endometrial cytosol
.and this is partly due to the fact that the measurement
of this receptor is hiridered by contamination of
cytosol with substantial amounts of plasma proteins
(Maass et al 1975). The plasma protein of particular
importance is SHBG which has been shown to have a high
affinity and low capacity for 5«-DHT (Vermeulen &
Verdonck 1968; Iqbal & Johnson 1979), similar to that
of androgens of the AR in the rat ventral prostate
(Davies et al 1977a). The presence of plasma protein
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in cytosol makes it difficult to estimate AR levels
using Dee separation of free and bound steroid when
[3H]5~-DHT is used as the ligand.
The principal technique previously used for endometrial
cytosols has been agar gel electrophoresis (Friberg et
a11978). However, this technique is slow and does not
allow rapid multiple sample analysis.
Mainwaring (1969) and Steggles & King (1970) have shown
that steroid proteins are acidic proteins which can be
selectively precipitated by protamine sulphate. This
procedure has been used for measuring AR in breast
cancer cell line (Hu et al 1975; Lippman et al 1976a)
and in human breast tumours (Lippman & Huff 1976b;
Allegia et al 1979) as well as in rat ventral prostate
(Blondeau et al 1975; Davies et al 1977a).
--, --
For measuring cytoplasmic and nuclear ARs in the rat
ventral prostate an assay has been reported by Davies
et al (1977b) using protamine sulphate precipitation
and incubation for 16 hours at 150e with [3H]5«-DHT.
No reports have been published stating the use of this
assay for measuring AR in endometrial tissue samples.
This assay was tested for the possible use in
endometrial tissue and after performing some kinetic
studies the assay was found to be unsatisfactory since
no visible precipitate was formed with protamine
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sulphate on addition of the cytosol. This may have
been due to the small size of endometrial samples
available for the assay.
The procedure then adopted for the measurement of AR in
the endometrium was that of Kato & Seto (1985). In
this procedure a synthetic androgen R1881 was used
instead of 5 -DHT and the Dee technique was applied.
The method proved to be satisfactory.
In the present study, cytoplasmic receptors for
progesterone, oestradiol and androgen have been
measured in endom~trial tissue from a number of women.
There is no significance between the steroid receptor
binding sites and age of patient nor between binding
sites and day of cycle (Figures 26a-c, 27 & 28).
In normal women (Figure 28), the concentration of
'steroid binding sites appeared to display a cyclic
variation during the menstrual cycle, although there
were only a small number of patients. Sandborn et al
(1979-)and Rodriquez et al (1979) have reported that
the concentration of both oestradiol and progesterone
receptors increase from very low levels, during the
proliferative phase of the menstrual cycle in normal
tissues and that these decline under the action of
progesterone secreted by the corpus luteum.
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The concept that endometrial response to progesterone
is defective in cases of subfertility is intriguing
and may have relevance to current programmes of in
vitro fertilisation and embryo transfer where pregnancy
rates are surprisingly low, although fertilisation
rates are high (Edwards 1981).
Glasser & Clark (1975) and Pelag et al (1979) have
reported that it is possible that, in a number of
cases, there is an appropriate response to steroids in
the decidualisation process which has been shown to be
dependent upon progesterone, at least in other species.
It is known that PR are measurable only after
oestradiol "priming" and indeed are only one of the
products of the increased protein synthesis induced by
oestrogen (Milgrom et al, 1973). Consequently any
defects or deficiency in progesterone action may be due
to a defective PR or a defective ER in subfertile
women.
Using Fisher's exact probability test there was a
significant (p = 0.007) difference between ER binding
in s~bfertile women and those of normals (Figure 29).
The primary subfertiles follow a cyclic variation,
whereas the secondary subfertiles show no variation.
The ER levels from ovulatory cycles are directly
dependent on the histological dated phase of the
menstrual cycle. The level is highest in late
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proliferative phase and declines during the secretory
phase. Luteal phase deficiency and other luteal phase
defects are connected with a decrease of ER
concentrations in secretory endometrium (Seliger et al
1987). The ER sites for secondary subfertiles are low
and the result of statistical analysis enabled the
null hypothesis to be rejected (p<0.05), since it
appears that there is a possible over-sensitivity of
the endometrium to oestrogen in the secondary
subfertile group during the cycle.
Cytoplasmic PR concentration binding sites of the
endometrial samples of the normal primary and secondary
subfertiles are shown in Figure 30. Overall levels
were similar but again there was a highly significant
difference between normals and primary subfertiles
(p = 0.0003) and normals and secondary subfertiles
(p = 0.0004).
Both oestradiol and progesterone receptors in the
endometrium are induced during the follicular phase,
reaching their maximum level around the time of
ovulation (Levy et al 1980). PR synthesis in target
tissues of oestrogen and progesterone is under
oestrogenic control (Haslam & Shyamala 1980). Thus,
the main factor promoting the induction of sex hormone
receptors in the endometrium is oestradiol, which is
secreted by the developing follicle.
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The small number of samples from patients with
secondary subfertility make it difficult to determine
whether such a steroid receptor defect is operative,
although it does seem unlikely. If such a fault is a
defect in the genetic material, then perhaps it is not
surprising that such a defect is not detectable since
all the women in this group have had at least one full-
term pregnancy. Maynard et al (1983) have reported
that in whole tissue studies, nuclear uptake of
progesterone is subnormal in the endometrium of women
with unexplained primary subfertility.
AR were detectable in the endometrial tissues. Levels
of receptors were low but appeared to display a cyclic
variation although there was only a small number of
subfertile patients (Figure 31). Androgen receptors
were measurable in the endometrium of subfertile
patients. M~kerjee (1972) and Mukerjee & Chakravarty
(1974), whilst working on the probable role of
'testosterone an~ the related androgenic steroids on the
female reproductive organs of rats, reported a potent
positive luteotrophic effect of testosterone and DHEA
in this species, as well as in the human female. The
presence of androgens in their study suggest that
androgens help to maintain the structural and
functional integrity of the corpus luteum. Androgens,
therefore, preserve and stimulate the corpus luteum to
produce more progesterone necessary to build up an
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adequate secretory endometrium and thus prepare the bed
for the fertilised ovum to be implanted (Mukerjee &
Chakravarty 1974). However, it is known that
testosterone increases the secretion of pitui tary
gonadotrophins (Loraine & Bell 1971). Also, it is
known that testosterone reduces the responsiveness of
the ovaries to pituitary gonadotrophins (Diczfalusy
1962)•
The role of an AR in endometrium tissue is unknown
(MacLaughlin & Richardson 1978), but Muechlers & Kohler
(1977) have shown that androgens influence the
development of t~e endometrium by binding with high
affinity to a specific AR.
In view of these results it would appear that
determination of AR together with ER in endometrial
tissues may be useful in predicting clinical response
in infertility to endocrine therapy.
5 -DHT and testosterone have been reported to compete
with oestradiol for the ER protein and reduce the
association constant of oestradiol (Korach & Muldoon
1975; Rochefort & Garcia 1976; Nicholson et al 1978).
In the present study the combined levels of 5 -DHT and
testosterone are higher than the levels of oestradiol
measured in the same tissue. Therefore, under in vivo
conditions, these androgens are unlikely to translocate
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the ER to the nucleus in endometrial tissue or have an
oestrogen antagonistic effect by interfering with the
binding of oestradiol to its receptor.
Although the androstenedione levels in tissues are
relatively high, the affinity of the ER for this C19-
steroid is very low. It is unlikely therefore that
there is sufficient androgen to compete with oestradiol
for its receptor in vivo, or to have a direct agonistic
or antagonistic effect on oestradiol action. Both
androstenedione and testosterone would, however, act as
readily available substrates for the aromatase enzyme
system (Tseng 1982a; Tseng et al 1982b; Tseng 1984a &
Tseng et al 1984b) and the oestradiol formed could, if
it is present in the cytoplasm, trans locate its
receptor to the nucleus and effect cell function.
Clomiphene citrate (Clomid) is an antioestrogen which,
via a negative feedback mechanism, increases the plasma
oestrogen conceritration. Clomid therapy for subfertile
women is derived from significantly increased pregnancy
rates in women treated (Drake et al 1978). Fleming &
Gurpide (1982) found that Clomid caused increased
follicular development as indicated by elevated pre-
ovulatory levels, but this was not followed by improved
progesterone levels.
Figure 32a shows that no significant difference could
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be demonstrated between normal women and subfertile
women taking Clomid in oestrogen receptor content.
Figure 32b demonstrates the reduced level of
progesterone binding site concentration in women taking
Clomid compared with women not on Clomid therapy. No
cyclic variation observed AR binding sites of women on
Clomid therapy (Figure 32c).
There was no significant correlation observed in ER
binding sites and serum oestradiol and also none
between PR binding sites and serum progesterone (Figure
33-34). The ER binding sites are higher than PR
binding sites in' the same endometrial tissue. The
interplay between oestrogen and progesterone on the
effect of their receptor level illustrates the
interhormonal control mechanism. Oestradiol binds to
its receptor to form the complex and translocate to the
nucleus. The complex is responsible for the oestrogen
responses that are characterised by increases in
'mitotic activity and cellular differentiation in
endometrium during the follicular phase. One of the
oestrogen responses is to stimulate the synthesis of
PR. The elevated PR in turn increases the activity of
the endometrium to respond to progesterone. During the
secretory phase progesterone binds to its receptor to
form the PR complex, which undergoes translocation to
the nucleus and elicits the characteristic progestional
responses to prepare endometrium for implantation and
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pregnancy. In addition, progesterone suppresses the
synthesis of ER and antagonises the proliferative
effect of oestradiol on the endometrium. Thus, the
interaction between the two steroids produces a
regulatory system that operates within the endometrial
cell.
In the present study a system was developed to assay
5~ -reductase activity in the human endometrium already
assayed for receptors. [3H]-5~-androstane-3,17-dione
was characterised as a metabolite of [3H]androstene-
3,17-dione incubated with the endometrium tissue
homogenates. NADPH was added as the required cofactor
which appeared to be common property for all described
5ex-reductases (Fredriksen & Wilson 1971; Gustafsoon
& Pousette 1974; Milewich et al 1979a and 1979b,
Koninckx et al 1979 and Enderle-Schmitt et al 1986)
,
with NADH not being capable of acting as a source of
hydrogen.
A common property for all "described 5~-reductases is a
relatively low stability and the activity of the enzyme
is found to decrease rapidly with time unless the
enzyme is frozen (Fredriken & Wilson 1971).
In this study incubations were carried out from frozen
endometrium, because fresh endometrium was not readily
available. All incubations were performed at 37oC. In
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this study the rate of production of S~-androstane-
3,17-dione from 4-androstene-3, 17-dione was to be
studied as a function of time. Also in this assay, a
product of the metabolism of androstenedione by 50<-
reductase, S ~ -androstanedione was characterised by the
isopolarity with authetic steroid on a TLC system.
However, it was apparent that a relatively small
percentage of the added substrate was recovered. This
deficiency may be due to unidentified polar metabolites
and not due to procedural losses.
It would have proved very useful to perform some
kinetics using this assay on endometrial tissue, but
this system was unsatisfactory (Figure 36 & 37), even
after modification. Perhaps this was because the
tissue used was not fresh, on thawing and freezing the
activity of enzyme could have been destroyed or may be
,
this system, could not be used for this particular
enzyme in this particular tissue.
study of the nuclear S~-reductase of rat prostate
showed that 30% of activity was lost when stored at
-80oC for 4 weeks. (Koninckx et al 1979) and similarly
for the nuclear SOC-reductase of human hyperplastic
prostatic tissues (Hudson 1981).
Hudson (1981) compared the conversion of testosterone
to DHTin the absence or presence of 3 cyproterone
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acetate concentrations and found that 10umol.l-1 and
10Oumol.l -1 cyproterone acetate was a competi tive
inhibitor of nuclear 5~-reductase of testosterone.
Since the higher concentration of DHT in human
hyperplastic prostatic tissue than is in normal tissue
has been confirmed by several investigators,
(Gustafsoon & Pousette 1974; Habib et al 1982; Geller
et al 1976; Rennie et al 1983; Martini et al 1986)
the demonstration that this antiandrogen competitively
inhibi ts the Scx.-reduction of testosterone is of
potential therapeutic significance.
The enzyme 5ot.-red.uctasecatalyses the conversion of
testosterone to S«-DHT which is an essential step in
the promotion of androgen action in target tissues such
as the epididymis, seminal vesicles and prostate.
This study has developed the basis of an effective
assay of S~-reductase activity in human endometrium.
The role of C1 g-steroids in the aetiology of
endometrial cancer has been the subject of many studies
and it is believed that these steroids may contribute
to the development and growth of endometrial carcinomas
by modifying oestrogen action in this tissue.
Furthermore, androgen receptors have been determined in
endometrial tissue and it is possible that the C19-
steroids may modify growth of this tissue through their
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own receptors. The analysis of 50< -DHT and
testosterone in the endometrial tissue showed that,
although these steroids are present in high
concentrations they are unlikely to interfere with
oestradiol action. Even though the level of
androstenedione was high, it is unlikely that this
steroid would modify oestrogen action as the affinity
of the ER for androstenedione.
The presence of AR has been demonstrated by using
saturation analysis. The role of this receptor protein
in normal and abnormal endometrium tissue is not clear
and must be eva~uated before it is possible to
determine whether the androgen levels measured can
modify the growth of these tissues.
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· APPENDIX
Protein Determination (Lowry 1951)
1. A standard solution of BSA 1mg/ml was taken.
2. To each standard tube, the following volume of
standard solution and distilled water was added.
standard Tube BSA (ml) Distilled (H2O)ml
1 0.2 1.8
2 0.4 1.6
3 0.6 1.4
4 0.8 1.2
5 1.0 1.0
6 1.2 0.8
7 1.4 0.6
8 1.6 0.4
9 1.8 0.2
10 2.0 0.0
3. For each sample (cytosol) the following
concentration was made up:
50 pI sample to 450 pl distilled water
4. Each tube was duplicated - for both standards and
samples - by transferring aliquots of 0.5ml from
each tube to 2 other tubes respectively.
5. To each tube 1ml of reagent was added, consisting
of:
50ml of 2% Na2co3 in 0.1M NaOH
1ml of 0.5% CuS04.5H20
1ml of 1% Na tartrate
Mixed vigorously and then left for 17 min on ice.
6. 0.1ml of Folin Ciocalteu's (FC) Reagent was added
(1ml F.C. to 2ml H20).
7. Left for 25 minutes on ice and 25 minutes off
ice, and then added 2ml of distilled H20 todilute.
8. The optical density (absorbance) of standards and
samples was measured at 750nm using the
spectrophotometer.
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9. A graph of optical density against amount of
protein was plotted. From this standard curve,
the amount of protein present in the sample tube
was calculated.
PROTEIN DETERMINATION - STANDARD CURVE
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Comparison of 3H: 14C ratios
Graphs of efficiency against ratio were obtained by
using external standards, where:-
14C = 203,000 dpm
3H = 517,000 dpm
1st June, 1979
1st December 1979
and by counting the standards using the ~ -scintillation
counter. An example of the typical curve obtained is
shown.
The comparison of channels ratios was used for the
calculation of per cent recovery.
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